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ABSTRACT 
 
 
 
The Role of Docosahexaenoic Acid in Mediating Mitochondrial Membrane Lipid Oxidation and 
Apoptosis in Colonocytes. (August 2004) 
Yee Voon Ng, B.S., University of Nebraska, Lincoln 
Chair of Advisory Committee: Dr. Robert S. Chapkin 
 
 
 
 Colon cancer is the second leading cause of cancer death in the United States. 
Epidemiological data indicate that the consumption of dietary fiber and fish/marine products 
favorably modulate colon tumorigenesis. Docosahexaenoic acid (DHA, 22:6n-3) from fish oil, 
and butyrate, a fiber fermentation product generated in colon, protect against colon 
tumorigenesis in part by inducing apoptosis.  We have shown that DHA is incorporated into 
mitochondrial membrane phospholipids, which enhances oxidative stress and mitochondrial 
membrane potential (MP) dissipation.  To elucidate the subcellular origin of oxidation induced 
by DHA and butyrate exposure, young adult mouse colonocytes (YAMC) were treated with 0-
200 µM DHA, linoleic acid (LA, 18:2n-6) or no fatty acid (control) for 72 h with or without 5 
mM butyrate for the final 6-24 h.  Real time analysis of cellular membrane lipid oxidation, as 
indicated by oxidation of a lipophilic vital dye, mitochondrial permeability transition (MPT), as 
characterized by MP dissipation, and cytosolic ROS production, as depicted by hydrophilic ROS 
reactive fluorophore accumulation, were measured by living cell fluorescence microscopy.  After 
24 h of butyrate treatment, DHA primed cells showed a 29% increase in lipid oxidation 
(p<0.01), compared to no butyrate treatment, which could be blocked by a mitochondria targeted 
antioxidant, MitoQ (p <0.05), whereas LA treatment did not show an effect.  In the absence of 
butyrate, DHA treatment, compared to LA, increased resting MP by 14% (p <0.01).  In addition, 
 iv
butyrate-induced MP dissipation was greater (20%) in DHA primed cells as compared to LA 
(10%).  This effect was blocked by pre-incubation with MPT inhibitors, cyclosporin A or 
bongkrekic acid at 1 µM.  These data suggest an increase in mitochondrial lipid oxidation and 
the resultant change in MP may contribute to the induction of apoptosis by DHA with butyrate as 
shown previously.  
 
 
 v
 
This thesis is dedicated ~ 
 
to my dearly missed godmother, Mdm. Quay, Siew-Ching,, 
 whose charisma has touched my soul; 
 
to my incredible parents, Mr. Ng, Ah-Hai and Mdm. Ong, Soo-Jit,  
whose unconditional love has nurtured and brought me up to be a decent person; 
 
to my two brothers, Kok-Ming and Kok-Leong, 
whose brotherly love has protected and saved me from many hurdles in life; 
 
to my beloved boyfriend, Mr. Wong, Wei-Suei 
who has supported me patiently; 
 
to all of my friends, who have taught me many good lessons in life; 
and lastly, 
 
to my major professor, Dr Robert S. Chapkin and lab-mates, who have provided me with all 
kinds of support during my years in graduate school at Texas A&M, College Station. 
 
“Thank you for your love and support!” 
 vi
TABLE OF CONTENTS 
 
            
 Page 
ABSTRACT........................................................................................................................  iii 
DEDICATION ....................................................................................................................  v 
TABLE OF CONTENTS.....................................................................................................  vi 
LIST OF FIGURES.............................................................................................................  viii 
LIST OF TABLES ..............................................................................................................  ix 
CHAPTER 
I INTRODUCTION  ..........................................................................................  1 
Diet, Tumorigenesis and Apoptosis—an Overview....................................  1 
Effect of Dietary Long Chain Fatty Acids on Cellular and Mitochondrial 
Membrane Structures ................................................................................  2 
n-3 PUFA and Oxidative Stress .................................................................  3 
Interaction Between Dietary Fatty Acids and Butyrate...............................  5 
Reactive Oxygen Species Regulates Cellular Events..................................  7 
Intracellular Formation and Propagation of ROS .......................................  8 
Mitochondrial Structure and Membrane Potential Changes   
during Apoptosis .......................................................................................  10 
Mitochondria Related Pro- and Anti-apoptotic Bcl-2  
Family Proteins .........................................................................................   11 
Oxidative Stress and Mitochondria Function .............................................  12 
Diet Modulates Mitochondrial Membrane Permeability Transition  
and Apoptosis ...........................................................................................  12 
 
II HYPOTHESIS AND OBJECTIVES OF STUDY............................................  14 
 
Hypothesis ................................................................................................  14  
Objectives .................................................................................................  14 
II MATERIALS AND METHODS.....................................................................  16 
 
Materials...................................................................................................  16  
Cell Culture...............................................................................................  16 
Fatty Acid and Butyrate Preparation and Incubation ..................................  17 
Lipid Oxidation and Lipid Antioxidants ....................................................  17 
Mitochondrial Membrane Potential ...........................................................   18 
 vii
CHAPTER   Page  
 
Cytosolic ROS Production.........................................................................  19 
Fluorescence Microscopy and Quantification ............................................  19 
Cell Death Detection Assay.......................................................................  20 
Cytotoxicity Study ....................................................................................  20 
Statistical Analysis ....................................................................................  20 
IV RESULTS ......................................................................................................  22 
DHA and Butyrate Synergistically Enhance Lipid Oxidation .....................  22 
Effects of Vitamin E Succinate and MitoQ ................................................   25 
Effects of Fatty Acids on Mitochondrial MP and MPT ..............................  27 
Apoptotic Phenotype.................................................................................  30 
Cytosolic Reactive Oxygen Species...........................................................  31 
 
V DISCUSSION AND SUMMARY ...................................................................  40 
Significance ..............................................................................................  45 
REFERENCES ...................................................................................................................  47 
APPENDICES ....................................................................................................................  56  
VITA ..................................................................................................................................  99 
 
 
 
 
 
 viii
LIST OF FIGURES 
 
FIGURE  Page 
1. Electron Transportation and Mitochondrial Complexes ..............................................  9 
 
2. Mitochondrial Permeability Transition Pores..............................................................     11 
 
3. Experimental Design and Timeline.............................................................................     17 
 
4. Effect of Fatty Acid and Butyrate Co-treatment on Membrane Lipid Oxidation ..........     23 
5A. Vitamin E Succinate Reduces Butyrate-induced Membrane Lipid Oxidation in            
YAMC Cells. .............................................................................................................  24 
 
5B. VEs (25 µM) Appears to Promote Lipid Oxidation in YAMC Cells............................  24 
 
6. MitoQ Prevents Lipid Oxidation Induced by DHA and Butyrate Co-treatment ...........     26 
 
7. Mitochondrial Membrane Potential Is Enhanced by DHA in a Dose Dependent           
Fashion in the Absence of Butyrate. ...........................................................................     28 
 
8. Effects of Fatty Acid Treatment on Mitochondrial Membrane Potential......................     29 
 
9. Selective Targeting of a Redox Active Antioxidant (MitoQ) to Mitochondria Does        
Not Block Apoptosis Induced by Fatty Acid and Butyrate Co-treatment as                
Indicated by DNA Fragmentation ELISA...................................................................     30 
 
10. Pair-wise Comparison of Reactive Oxygen Species Production Between No Butyrate           
and 5 mM Butyrate Treatment at the Same Incubation Time, Treated with the Same     
Fatty Acid..................................................................................................................  32 
 
11. Putative Mechanism by Which the Incorporation of DHA into Mitochondrial  
Membrane Phospholipids Results in an Increase in Membrane Potential.....................   46 
 
 
 ix
LIST OF TABLES 
 
 
TABLE  Page 
1. Effect of Fatty Acid and Butyrate Co-treatment on Membrane Lipid Oxidation ............  33 
2. Vitamin E Succinate (VEs) Reduces Butyrate-Induced Membrane Lipid Oxidation                  
in YAMC Cells .............................................................................................................  34 
3. MitoQ Prevents Lipid Oxidation Induced by DHA and Butyrate Co-treatment ..............  35 
4. Mitochondrial Membrane Potential Is Enhanced by DHA in a Dose Dependent                  
Fashion in the Absence of Butyrate ...............................................................................  36 
5. Effect of Fatty Acid Treatment on Mitochondrial MP....................................................  37 
6. Pair-wise Comparison of ROS Production Between No Butyrate and 5 Mm Butyrate 
Treatments of the Same Incubation Time, Treated with the Same Fatty Acid.................  38 
7. Selective Targeting of a Redox Active Antioxidant (MitoQ) to Mitochondria Does                
Not Block Apoptotic Induction by Fatty Acid and Butyrate Co-treatment......................  39 
 
 
 1
CHAPTER I 
INTRODUCTION 
Colon cancer is the second most prevalent type of cancer and is a leading cause of cancer 
death in the United States and in essentially all economically developed countries (1).  Over 
940,000 cases of colorectal cancer occur annually worldwide, among which North America is one 
of the continents reporting the highest incidence rate.  It is noteworthy that 50% of these cases 
result in death (1, 2), i.e. colorectal cancer is responsible for some 470,000 deaths each year, 
among which 57,100 are Americans (1).  Nevertheless, it is estimated that 70% of colorectal 
cancers are preventable by moderate changes in diet and lifestyle.  For instance, the European 
Prospective Investigation into Cancer and Nutrition (EPIC) suggests that a daily consumption of 
500 grams (1.1. lbs.) of fruits and vegetables can decrease incidence of cancers of the digestive 
tract by up to 25% (2).   
 
Diet, tumorigenesis and apoptosis—an overview  
Epidemiological studies indicate that populations ingesting higher amounts of fish are at a 
lower risk for colon cancer and a lower mortality rate of colorectal cancer (3-5), compared to those 
ingesting diets high in saturated fat or other polyunsaturated fatty acids (PUFA).  These studies 
indicate a chemoprotective role for omega-three (n-3) PUFA.  Dietary fibers also play a favorable 
role in the prevention of colon carcinogenesis (5-7).  Different combinations of long chain PUFA 
and fibers in the diet modulate colon tumorigenesis.  Most recently, dietary fish oil, and fiber, such 
as those from fruits and vegetables, in combination has been demonstrated to be beneficial in the 
prevention of colon cancer (3, 8).  In a rat model of colon carcinogenesis, diets containing 
fermentable fiber and fish oil have been shown to protect against colon tumorigenesis, compared to 
_______________  
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diets rich in cellulose and corn oil (7, 9).  
With regard to dietary intervention, apart from cell proliferation and differentiation, multi-
step programmed cell death, i.e., apoptosis, has been extensively investigated as a biological 
marker regulating colon cancer risk.  Cancer studies at the cellular level provide evidence that an 
abnormality in the molecular expression, configuration, functionality and/or interaction of 
proapoptotic signaling molecules contribute independently or synergistically to the inhibition of 
cancer cell growth (see review (10)).  For instance, reactive oxygen species (ROS) and their 
counterparts, intracellular antioxidants, are involved in a multitude of biological effects including 
mutagenesis, tumor promotion, regulation of proliferation, activation or inactivation of 
biomolecules, regulation of transcriptional activities as well as the activation and execution of 
apoptosis.  
 
Effect of dietary long chain fatty acids on cellular and mitochondrial membrane structures 
 
 Together with eicosapentaenoic acid (EPA, 20:5n-3), docosahaexenoic acid (DHA, 22: 6n-
3) is a member of n-3 PUFA family found in high concentration in fish oil.  Dietary fatty acids are 
incorporated to cell membrane phospholipids and have effects on, but not limited to, cell 
membrane composition and function (9, 11), membrane lipid oxidation (12, 13), transcriptional or 
translational regulation (14, 15), eicosanoid biosynthesis (15) and molecular signal transduction 
(10).  These pleiotropic effects are believed to contribute to the observation that dietary fish oil, 
specifically n-3 PUFA, suppresses the initiation and promotion phases of colon cancer 
development.  
Cumulative evidence shows that n-3 PUFA, in contrast to n-6 PUFA, uniquely affect cell 
cytokinetics by altering the cellular microenvironment through changes to membrane composition, 
thereby promoting apoptosis (7, 16-18).  In animal studies, supplementing diets with fish oil, a rich 
source of EPA and DHA, significantly alters tissue levels of these fatty acids.   n-3 PUFA from fish 
oil or purified ethyl esters were incorporated into colonocyte mitochondrial membrane 
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phospholipids (16, 18), which coincided with the enhancement of apoptosis in the colon (7, 19).  A 
similar trend was observed utilizing colonocyte cell lines, in which the incorporation of DHA into 
cardiolipin, a mitochondrial membran:e phospholipid, was associated with the induction of 
apoptotic signaling (11, 17).  To date, the significance of fatty acid incorporation into membrane 
lipids in relation to the induction of apoptosis has not been determined.  We hypothesize that the 
incorporation of n-3 PUFA increases cell susceptibility to oxidative damage, and subsequently 
perturbs the integrity of mitochondrial membranes. 
 
n-3 PUFA and oxidative stress 
Dietary n-3 PUFA may increase apoptosis in colonocytes via a mechanism involving ROS 
production (20).  We have shown that an increase in ROS production following fish oil 
supplementation in the diet is correlated with the induction of apoptosis in colonic crypts (21, 22).  
In addition, data from cell culture studies have demonstrated that DHA treatment increases ROS 
production and induces apoptosis (11, 13, 16).  Furthermore, antioxidants, which specifically target 
membrane lipid oxidation, partially reverse the effect of DHA-induced apoptosis in human colon 
carcinoma cells (17).  This evidence in its entirety suggests that oxidative stress, in particular lipid 
oxidation may favorably modulate apoptosis in cells enriched with n-3 PUFA.  It is noteworthy that 
even though EPA and DHA are both n-3 PUFA, they may exert protective effects against colon 
cancer through independent mechanism (23, 24).  In the present study, DHA was used to determine 
the mechanism by which dietary fish oil relative to corn oil, reduce colon cancer risk. 
DHA is a long chain n-3 PUFA, and compared to linoleic acid (LA, 18:2n-6), the major 
PUFA constituent of corn oil, is more susceptible to oxidation (25).  The pro-oxidative properties 
of DHA are attributable to both the position and the number of its double bonds.  Specifically, the 
oxidation of PUFA is linearly dependent on the number of double bonds present (13, 25).  Ex vivo 
data have also shown that colonocytes are capable of incorporating substantial quantities of EPA 
and DHA, each of which contains five and 6 double bonds, respectively, are highly susceptible to 
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lipid oxidation (18, 19, 23).  Interestingly, the number of fatty acid double bonds, ROS levels, and 
the proportion of cells undergoing apoptosis in cancer cell lines has been correlated (9, 13).  In 
addition, with respect to fatty acid class, n-3 PUFA, e.g., DHA is more susceptible to oxidation 
compared to n-6 PUFA, e.g., LA (20).  Collectively, these data support our hypothesis that n-3 
PUFA, found primarily in fish oil, can induce apoptosis through a mechanism involving the 
oxidation of membrane phospholipids.   
The oxidation of PUFA during metabolic stress gives rise to a series of toxic α,β-
unsaturated aldehydes, i.e., enals, including the electrophile, 4-hydroxy-2-nonenal (4-HNE). With 
respect to additional/alternative mechanisms of action, these class of lipid oxidation products could 
be cytotoxic and may be pro-apoptotic (26-28).  In vivo, animal studies examining the effect of 
dietary fish oil or DHA supplementation on DNA lesion formation showed that a fish oil/DHA 
fortified diet significantly increased oxidative damage (20) but decreased the net DNA adduct (8-
oxodeoxguanine; O6-methylguanine) levels in colonocytes (29).  These observations suggest that 
dietary fish oil protects intestinal cells against oxidative DNA damage in part via deletion 
mechanisms, since the increase of DNA lesion was coupled to an incremental activation of 
apoptosis (27, 29, 30).   
In addition to increasing oxidative stress by giving rise to pro-oxidants, DHA has the 
ability to modulate gene transcription and the homeostasis between ROS and antioxidants, thereby 
rendering cells more susceptible to apoptosis.  Specifically, DHA has been found to induce lipid 
oxidation indirectly by influencing gene transcription.  PUFA, in general, are capable of enhancing 
the activation of PPAR-α, which subsequently has been linked to the induction of several genes 
encoding proteins responsible for lipid transportation and oxidation (14).  Collectively, these data 
suggest that DHA may be pro-oxidative and pro-apoptotic via several overlapping mechanisms.   
To further illustrate the importance of oxidative stress and antioxidants balance with regard 
to apoptosis induction, several studies have examined the activities and expression levels of 
intracellular antioxidants (31, 32).  Endogenous antioxidants may attenuate ROS-induced cell 
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damage and reduce cell death, initiated by pro-oxidants, such as n-3 PUFA.  In vivo, colon 
epithelial cells expressed a greater endogenous antioxidant capacity in part as a compensatory 
mechanism towards chronic oxidative stress exposure, compared to the small intestine, sharing 
similar morphology (33).  It is now readily apparent that, besides being pro-oxidative, n-3 PUFA 
are capable of suppressing the activity and expression of intracellular antioxidant enzymes, thereby 
enhancing tissue susceptibility towards oxidative stress and subsequent apoptosis induction (20, 32, 
34).  For example, the activities of endogenous antioxidants, such as glutathione transferase, 
glutathione reductase, glutathione peroxidase, and catalase appear to be depleted in animals fed a 
diet enriched with n-3 PUFA compared with diets supplemented with n-9 monounsaturated fatty 
acid or with n-6 PUFA (35).  In a preliminary study, we have also demonstrated that in the colonic 
crypts of animals fed a fish oil/pectin supplemented diet, the antioxidant activities of catalase and 
superoxide dismutase were lowered (33) resulting in an increase in ROS and oxidative stress.  Thus 
far, from a disease prevention standpoint, accumulating evidence suggests that n-3 PUFA or DHA 
promote cancer cell death.  These data suggest that the perturbation of redox balance within a cell 
may be beneficial to the host under certain biological conditions, especially in malignant host cells.  
 
Interaction between dietary fatty acids and butyrate 
In conjunction with n-3 PUFA, which have anti-carcinogenic and anti-tumorigenic effects, 
butyrate in the lumen may synergistically modulate colon carcinogenesis by enhancing or inducing 
ROS production in vivo (36-38).  Our preliminary data show that the feeding of pectin, a 
fermentable fiber that increases luminal butyrate levels, upregulates ROS production in the 
proximal colon, primarily in rats fed a fish oil supplemented diet (22, 30, 33).  Ex-vivo incubation 
of rat colonic crypts with physiological concentrations of butyrate also exhibited a similar ROS up-
regulation property (9).  In contrast, n-6 PUFA incorporation into colonic epithelial cell 
mitochondrial membranes in corn oil fed rats resulted in a decrease in ROS levels following 
butyrate treatment (19).   
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Butyrate, along with other short chain fatty acids (SCFAs), mainly acetate and propionate, 
is produced in the colonic lumen by microorganisms via the break down of complex carbohydrates 
and fermentable fibers (e.g., pectin from fruits and vegetables).  Among the SCFAs produced, 
butyrate is the most efficient energy source and the most potent inhibitor of colon cancer invasion 
(6, 39).  It is an essential energy source capable of activating apoptotic pathways in colonocytes.  
Mice with a homozygous deletion of the gene for short chain acyl dehydrogenase, which encodes 
an enzyme necessary for the mitochondrial β-oxidation of SCFAs, showed a reduced ability to 
metabolize butyrate, resulting in a greater than 90% decrease in apoptosis in colonocytes (6).  
Localized to the gut, fiber fermentation permits colon epithelial cells to have direct access 
to an energy source, and creates a channel for butyrate to modulate colon cancer development 
through epigenetic or genetic means.  It is noteworthy that the efficacy of butyrate uptake is 
dependent on factors such as the co-existing substrate in the lumen (40) and the pathogenesis phase 
of the mucosa (41).  In addition, butyrate could modulate colon tumorigenesis via a gene 
transcription regulated pathway (42).  Hence, the effects of butyrate may take time to appear and 
could be subtle in nature.  
Butyrate can induce cellular oxidative stress and can modulate cellular gene expression 
leading to changes in cell cycle arrest, maturation, differentiation, as well as apoptosis (36-38, 42).  
These paradoxical effects of butyrate may be determined by the state of activation of the cells, such 
as the timing and the amount of butyrate administered, the source of butyrate, and the interaction 
with dietary fat (43, 44).  
With respect to alternative mechanisms to induce apoptosis, early studies showed that 
butyrate is a potent histone deacetylase (HDAC) inhibitor, which causes nonspecific 
hyperacetylation of histones and successive alteration in gene expression (42, 45) in favor of colon 
cancer cell death.  In addition, butyrate treatment can increase mitochondrial protein expression, 
which appears to be related to the enhancement of mitochondrial function and the induction of 
apoptosis in colonic epithelial cells (46).  Our preliminary data, in particular, have shown that 
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butyrate may activate apoptosis through the activation of Fas/Fas-L and/or a mitochondrial 
regulated pathway (9, 47).  In summary, data from these studies suggest that various mechanisms 
may account for the protective effects of butyrate against colon cancer.  For the purpose of this 
study, oxidative stress induction and the mitochondrial-targeted apoptosis activation properties of 
butyrate were investigated.  
Due to the complex interaction among dietary components, the ability and the effectiveness 
of butyrate to upregulate apoptosis and to protect against colon tumorigenesis appears to be 
dependent on the dietary lipid source, with fish oil being more protective than corn oil (9, 16).  In 
immortalized mouse colon cell lines, the ability of PUFA, including DHA and LA to promote 
apoptosis was enhanced by a 24 h incubation with ≥ 1mM butyrate (16).  Herein, we have 
hypothesized that butyrate creates a permissive environment for apoptosis in part by enhancing n-3 
PUFA-induced oxidative stress. 
 
Reactive oxygen species regulates cellular events   
Preexisting oxidative stress levels within a cell differentially modulate cell sensitivity 
towards successive ROS assault (33, 37, 48).  Under basal conditions or when transient oxidative 
stress is encountered, some cell populations have adapted to the existence of reactive intermediates 
by evolving defense mechanisms that either scavenge these intermediates or repair the damage they 
cause.  On the other hand, a transient oxidative stress surge may also lead to cell death through 
apoptosis or necrosis and inhibit proliferation in some cell lines, which most probably does not 
favor cancer progression (28).  It is possible therefore that ROS may represent key elements for 
selective and efficient apoptosis induction by natural antitumor systems (49).  
On the other hand, following prolonged exposure to oxidative stress, cells may become 
hyper-resistant to ROS-induced apoptosis, an event contributing to aging and to carcinogenesis 
(50).  Interestingly, fish oil and butyrate are potent inducers of apoptosis, especially in malignant 
transformed cells that may be chronically overexposed to oxidative stress.  Dietary fish oil or DHA 
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capable of altering the oxidative balance in colonocytes to rectify an increase in oxidative stress, 
could promotes apoptosis (3, 5, 17, 29, 34).  
 
Intracellular formation and propagation of ROS 
During aerobic metabolism, oxidative damage can accumulate in the mitochondria relative 
to the rest of the cell because electrons continually leak from the respiratory chain to form 
damaging ROS (49, 51).  This oxidative damage impairs mitochondrial ATP synthesis and Calcium 
(Ca++) homeostasis and may induce the opening of the mitochondrial permeability transition (MPT) 
pores, thereby triggering necrotic or apoptotic cell death (52, 53).  
Within the inner mitochondrial membrane, NADH is oxidized to NAD+ by NADH-
Ubiquinone reductase, while FADH2 is oxidized to FAD by succinate-Ubiquinone reductase.  The 
electrons from NADH and FADH2 are both transferred to Ubiquinone, generating Ubiquinol.  
Located near complexes I, II and III is Ubiquinone (Q), which receives 2 electrons (to form 
Ubiquinol) from complex I and II and further passes electrons to complex III (to form Ubiquinone).  
In addition, Ubiquinone can donate electrons to oxygen to form superoxide (O2.-) (and Ubiquinol) 
thereby transferring ROS into the aqueous mitochondrial matrix.  Ubiquinone is recycled to 
Ubiquinol and continues serving as an antioxidant within the inner mitochondrial membrane (51).  
Electrons flow from Ubiquinol through a series of cytochromes to oxygen, the ultimate acceptor of 
electrons, which is reduced to water at complex IV.  The transfer of electrons along mitochondrial 
complexes I, III and IV are coupled to the pumping of protons from the mitochondrial matrix to the 
inter membranes space (Fig. 1).  The extrusion of protons from the mitochondrial matrix generates 
a pH gradient and an electrical potential difference across the membrane, which together constitute 
the proton motive force that drives ATP synthesis (54).  Protons are translocated down a gradient 
through complex V to produce ATP.   
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Fig. 1. Electron transportation and mitochondrial complexes. Electrons (e-) are transported down 
mitochondrial complexes I, III and IV, a process coupled to the pumping of protons (H+) from inside of the 
inner membrane to the inter membrane compartment.  This electron transport process results in the leakage of 
superoxide (O2-) and the initiation of ROS propagation.  
 
 
Incomplete reduction of oxygen during aerobic metabolism generates O2.-.  It is estimated 
that up to 10% of the reducing equivalents from NADH can leak out of the respiratory chain in the 
form of O2- (54).  Mitochondria have the ability to counter oxidative stress hyper-production, i.e. 
electron transport and leakage, and damage by shunting H+ back to the mitochondrial matrix. Via 
the effect of a group of Uncoupling Proteins or through allosteric inhibition of the electron 
transport chain by ATP/ADP ratio through a negative feedback mechanism (54), hyper-production 
of oxidative stress could be regulated.  
In many cases, the initially generated reactive intermediates in the mitochondrial 
respiratory chain convert cellular constituents into second-generation reactive intermediates capable 
of inducing further damage.  Specifically, the majority of O2.- generated is dismutated to form 
H2O2, while some serves as a substrate in Fenton reactions or can react with nitric oxide to generate 
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other reactive nitrogen species and electrophiles.  Among all, α,β-unsaturated aldehydes are the 
most studied membrane phospholipid oxidation products capable of denaturing protein or nucleic 
acids (20, 28) and causing apoptosis in some models (55). 
 
Mitochondrial structure and membrane potential changes during apoptosis 
The permeability transition (MPT) pore is a multiprotein complex formed at the contact 
site between the mitochondrial inner and outer membranes (Fig. 2).  This multiprotein complex is 
constituted primarily of a voltage dependent anion channel (VDAC), anion nucleotide transferase 
(ANT) and cyclophylin-D (56-58).  The MTP pore is directly involved in the regulation of 
mitochondrial matrix Ca++, transmembrane potential and cellular activation of apoptosis.  The 
binding of cyclosporin A (CsA) to cyclophylin-D and bongkrekic acid (BKA) to ANT, inhibits 
MPT activation, subsequently preventing the dissipation of mitochondrial membrane potential 
(MP) (57, 59, 60).  
MPT is characterized by a sustained opening of MPT pores, following a Ca++ overload in 
the mitochondria inner compartment (53, 57, 61), leading to apoptosis.  The full-blown activation 
of MPT pores permits a non-specific release of soluble mitochondrial proteins from the 
intermembrane space during MPT (53, 57).  Some well-studied mitochondrial proteins being 
released can serve as apoptosis inducing intermediates, i.e. cytochrome C and SMAC/DIABLO, by 
amplifying or transmitting apoptotic signals.  On the other hand, transient or full-blown MPT 
activation has always been coupled by dissipation of the MP as a result of the disruption of the 
inner mitochondrial membrane and the inability of membranes to maintain a proton gradient. These 
changes occur in most, if not all, models of cell death and can be taken advantage of to detect 
apoptosis at an early stage.  In addition, changes in the inner mitochondrial membrane and the 
permeability transition of the mitochondrial membrane are coupled in most cases to a series of 
catabolic reactions, which result in cell death (62).  Interestingly, during the activation of the 
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energy requiring apoptosis, only a few polarized mitochondria can be detected, because a 
subpopulation of respiring mitochondria within an individual cell generate ATP needed for the 
completion of the apoptotic cascade (63). 
 
 
     
Fig. 2. Mitochondrial permeability transition pores. The mitochondrial permeability transition pore 
contains the voltage dependent anion channel (VDAC) and the anion nucleotide transferase (ANT). 
Cyclosporin A (CsA) and Bonkrekic acid (BKA) inhibit membrane permeability transition through binding 
to Cyclophilin D (D) and ANT, respectively. 
 
 
 
Mitochondria related pro- and anti-apoptotic Bcl-2 family proteins 
The activation of the MPT and subsequent dissipation of MP appears to be an early 
apoptotic event regulated by members of the Bcl-2/Bax family, and is irreversible in many cell 
lines, such as colon epithelial cells (9, 48, 62).  Bcl-2 family proteins, which reside within 
mitochondrial membranes or the inter-membrane space, demonstrate unique binding domains for 
one another that affect their activation and function (64).  These proteins dimerize or oligomerize 
with one another to induce or inhibit apoptosis, depending on their pro-apoptotic or anti-apoptotic 
roles (57).  For example, the pro-apoptotic Bid protein and its truncated form (tbid) have a BH3 
only domain, which is required for the dimerization or oligomerization with other pro-apoptotic 
mitochondrial proteins to induce mitochondrial-involved apoptosis (64).  In addition, tBid 
BKA, ADP 
Ca++, ATP
CsA 
Inner
Mitochondrial 
Membrane
Outer
Mitochondrial 
Membrane
A
N
T
: Activation    : Inhibition  
Butyrate 
V
D
A
C
D 
D 
 12
specifically targets to the mitochondria via cardiolipin binding (65), causing the release of 
holocytochrome C, which is an effector in a cascade of events leading to apoptosis (65, 66). 
We have found that fish oil feeding increases apoptosis while decreasing Bcl-2 expression 
in colonic crypts of carcinogen injected rats (67).  In addition, butyrate via an unknown 
mechanism, also enhanced cytochrome-C translocation from the mitochondrial to the cytosolic 
compartment in rats fed a fish oil or n-3 fatty acid ethyl ester rich diet (9).  Hence, we have 
hypothesized that DHA and butyrate induce apoptosis through a mitochondria mediated pathway. 
 
Oxidative stress and mitochondria function  
The precise role of mitochondrial ROS and membrane lipid oxidation in colon cell death 
remains elusive.  A plethora of publications have shown that a oxidative assault triggers MPT 
thereafter activating apoptosis in many cell lines (49, 52, 53, 68).  In addition, it is noteworthy that 
a full-blown MPT and ROS production may amplify each other to warrant an induction of 
apoptosis (53). 
To date, limited evidence links n-3 PUFA and MPT directly to apoptosis in colonic 
epithelial cells.  Herein, we investigated whether DHA and lipid oxidation of mitochondrial 
membrane phospholipids, followed by oxidative activation of MPT, is capable of triggering 
colonocyte apoptotic pathways.  
 
Diet modulates mitochondrial membrane permeability transition and apoptosis 
Dietary factors may alter the metabolism and redox balance within mitochondria, thereby 
priming cells for the induction of apoptosis.  The acyl groups of mitochondrial phospholipids, i.e. 
cardiolipin, glycerophosphocholine and glycophosphoethanolamine, are altered in rats fed diets 
differing only with respect to fatty acid content (9, 11).  Interestingly, we have shown that the 
incorporation of n-3 PUFA into glycophosphoethanolamine is associated with the dissipation of 
MP (19).  In addition, butyrate treatment and butyrate/n-3 PUFA co-treatment have been shown to 
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enhance cytochrome-C relocation (9), MP dissipation and apoptosis in colonocytes (17, 46, 47).   
We were able to demonstrate that the pronounced effect of n-3 PUFA or dietary fish oil on 
apoptosis can be reproduced in a cell culture model.  Previously, using young adult mouse colonic 
(YAMC) epithelial cell lines, we have demonstrated that incubation with DHA increases caspase-3 
activity, i.e. a marker for apoptosis (16).  The conditionally immortalized mouse colon cell line, 
YAMC, bears a SV-40 heat sensitive large T antigen gene and can escape cell cycle arrest 
regulated by p53 and retinoblastoma when incubated in a permissive environment (33˚C with 5% 
CO2) with γ-interferon (16, 47, 69, 70).  p53 signaling regulates cell cycle delay and apoptosis in 
colon carcinoma cells (71, 72).  Studies have suggested that dietary factors may differently affect 
p53-dependent and p53-independent pathways to colon cancer (72).  This is relevant because 
butyrate is capable of inducing apoptosis in several human colon carcinoma and adenoma cell lines 
in a p53-independent manner (47, 69, 73).  Furthermore, mutations in the p53 tumor suppressor 
gene have been found in more than 50% of human colon tumor cell types (73-75). These data in its 
entirety suggests that YAMC cells culture is an appropriate model to further investigate the 
mechanism by which DHA and butyrate modulate mitochondria function.  
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CHAPTER II 
HYPOTHESIS AND OBJECTIVES OF STUDY 
Hypothesis 
The incorporation of n-3 PUFA increases cell susceptibility to oxidative damage, and 
subsequently perturbs the integrity of mitochondrial membranes, a process potentiated by butyrate. 
 
Objectives 
 
1. To quantify cellular and mitochondrial membrane lipid oxidation in colonocytes 
following n-3 and n-6 PUFA incubation. 
 
Lipid oxidation was detected using diphenyl-1-pyrenylphosphine (DPPP). DPPP is a novel 
non-toxic lipophilic fluorochrome that is retained within lipid membrane compartments, wherein it 
reacts specifically with lipid hydroperoxides to yield fluorescent DPPP-oxide (76). The 
fluorescence of this oxidized vital dye allows for quantification of membrane oxidant production in 
living cells.  
Our previous data has shown that n-3 PUFA increases cytosolic, i.e. water soluble, ROS 
production in rat colon primary cultures (22, 30).  To extend these observations and to assess 
membrane lipid oxidation, we investigated whether n-3 PUFA incorporation enhances membrane 
lipid oxidation in colon cell cultures. YAMC cells pretreated with BSA complexed-DHA (n-3 
PUFA) or -LA (n-6 PUFA) at 50 µM with or without the addition of 5 mM butyrate were examined 
with respect to lipid oxidation. 
2. To determine the association between membrane lipid oxidation and mitochondrial 
function. 
 
MPT pore opening is an early and a pivotal event in the mitochondria-dependent apoptotic 
pathway, resulting in the dissipation of MP (∆Ψmt) and the induction of apoptosis (56).  The 
relative levels of MP following butyrate/fatty acid co-incubation and under basal conditions were 
measured using a cell permeant, cationic lipophilic fluorescent dye, i.e., Rhodamine 123 (Rhd123) 
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as described previously (9, 77).  Briefly, this fluorescence probe is accumulated in mitochondrial 
matrix by the MP and lipid solubility.  In general, a stable real time MP level indicates a dynamic 
equilibrium of the probes entering and leaving the mitochondrial matrix, i.e., the accumulation of 
Rhd 123 may fluctuate as the environmental factors (e.g. temperature) change, hence a time 
matched control is used for normalization for each treatment.  
To determine if lipid oxidation is localized within mitochondrial membrane phospholipids, 
we evaluated the effects of MitoQ.  MitoQ refers to a mixture of mitoquinone (oxidized) and 
mitoquinol (reduced) moieties, which are the two redox forms of mitochondria-targeted quinones.  
The antioxidant activity of MitoQ is associated with mitoquinol’s ability to take up electrons from 
the vicinity of complexes I and II and to donate them to complex III of the respiratory chain or to 
oxygen to form O2.- at the aqueous phase (78, 79).  This reduced moiety is also recyclable within 
the respiratory chain through redox reactions. Based on a study by Kelso et al. (78), the covalently 
attached triphenylphosphine cation and lipophilic alkyl chain of MitoQ contribute to its uptake and 
accumulation within the matrix face of the inner mitochondrial membrane, where most of the 
mitochondrial ROS production occurs. The driving force of MitoQ uptake is the membrane 
potential. While mitochondrial MP is the greatest MP among all organelles, it is assumed the 
preferential and predominant accumulation of MitoQ is localized to the mitochondrial compartment 
(61, 79). 
3. To determine if butyrate potentiates lipid oxidation and the alteration of mitochondrial 
function in colonocyte membranes enriched with n-3 and n-6 PUFA. 
 
Select YAMC cultures were incubated with butyrate (0-10 mM) for 6, 12 or 24 h with 
BSA-complexed DHA or LA (50 µM) or with no fatty acid for 72 h.   Butyrate or vehicle (RPMI 
1640 complete media) was incubated as indicated in protocol #A-5.  Lipid oxidation and MP 
dissipation were measured using fluorescence microscopy imaging techniques. 
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CHAPTER III 
MATERIALS AND METHODS 
 
Materials  
RPMI 1640 and Hanks’ balanced salt solution (HBSS) were from Mediatech (Herndon, 
VA).  Fetal bovine serum was from Hyclone (Logan, UT).  Insulin, transferrin, selenium without 
linoleic acid were obtained from Collaborative Biomedical Products (Bedford, MA).  Leibovitz 
buffer, Glutamax™ and recombinant mouse interferon-γ (γ-IFN) were from GIBCO BRL (Grand 
Island, NY).  Fatty acids were purchased from Nuchek Prep (Elysian, MN).  The fatty acid free 
bovine serum albumin (BSA) for fatty acid preparation, Cell Death Detection ELISA, Plus and 
Cytotoxicity-Detection (LDH) kits were from Roche Applied Science (Indianapolis, IN).  
Fluorescence probes, diphenyl-1-pyrenylphosphine (DPPP), Rhodamine 123 (Rhd 123), 5-(and-6)-
chloromethyl-2',7'-dichlorodihydrofluorescein diacetate acetyl ester (CMH2-DCFDA) were from 
Molecular Probes (Eugene, OR).  Cyclosporin A (CsA) was from Calbiochem (San Diego, CA).  
MitoQ was a gift from Dr. Michael Murphy (Medical Research Council Dunn Human Nutrition 
Unit, Cambridge, UK).  All other reagents were obtained from Sigma (St Louis, MO). 
 
Cell culture 
YAMC cells were obtained from R.H. Whitehead, Ludwig Cancer Institute, Melbourne, 
Australia (70).  For all fluorescence assays, prior to fatty acid pretreatment, 4-5x103 YAMC cells 
(passages 17-23) per well were seeded into two wells sterile #1 German borosilicate chambered 
cover glasses (Nalge Nunc, # 155380) for 24 h to achieve 50-70% confluence. Under a permissive 
temperature, 33°C, mycoplasma free cultures were grown in RPMI 1640 complete media 
supplemented with 5000 u/L γ-IFN, 5% fetal calf serum, 1% insulin/transferrin/selenium without 
LA. For the Cell Death Detection assay, cells were incubated in 35 mm cell culture dishes at 
35,000 cells per dish. See Fig. 3 for experimental design and timeline. 
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Fig 3. Experimental Design and Timeline 
 
Fatty acid and butyrate preparation and incubation 
DHA and LA were delivered to cells complexed to bovine serum albumin (BSA). To make 
the FA stock solutions, sodium salts of DHA and LA were complexed to fatty acid-free BSA in a 
4:1 molar ratio, filter sterilized and stored in smaller aliquots in a freezer at -20˚ C (47).  2.5 mM 
BSA complexed fatty acid stock solutions were prepared and used within one-month period.  LA is 
considered chemopromotive and served as the control in all experiments (16, 19).  
Upon reaching 50-70% confluence, YAMC cells were pre-treated with or without DHA- or 
LA-BSA complex for 72 h at 50 µM.  Co-incubation with 0, 1 or 5 mM sodium butyrate or 
isobutyrate (negative control) dissolved in complete RPMI 1640 media was initiated during the 
final 6, 12, or 24 h of fatty acid pre-treatment.  Isobutyrate is a branched-chain isoform of butyrate 
previously shown to induce neither differentiation nor apoptosis in colonic cell lines (80).  The 
working solutions were filter sterilized before use. 
 
Lipid oxidation and lipid antioxidants 
Following fatty acid treatment, cells were washed twice with phosphate buffer saline 
Day 1 Day 3 Day 2
0-200 µM FA-BSA treatment 
0-10 mM 
butyrate 
treatment 
Seed Grow Treat Assay 
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solution (PBS) and loaded with 5 µM DPPP (final concentration) for 10 min in the dark at room 
temperature.  The relative levels of DPPP-oxide fluorescence intensities were monitored using 351 
nm (excitation) and 380 nm (emission).  
Each analysis was performed under basal or oxidative stress conditions, i.e. with or without 
25-100 µM cumene hydroperoxide (CumOOH) or 10 µM hydrogen peroxide (H2O2), to serve as a 
control.  Due to the solubility of these compounds in the lipid bilayers, they differentially react 
with DPPP.  CumOOH initiates lipid oxidation in the membrane, while H2O2 generates peroxides 
primarily and initially in the cytosol without affecting membrane oxidation (76). 
To determine the association between PUFA treatment and lipid oxidation in the 
mitochondrial membrane, select cultures were treated with the mitochondrial targeted antioxidant, 
10-(6'-ubiquinoyl) decyltriphenylphosphonium bromide (MitoQ) at 1 - 50 µM (78).  2.5 or 5 µM 
MitoQ was loaded one or 24 h prior to dye loading, i.e. during the last one hour or during the 24 h 
butyrate loading period. This antioxidant is expected to selectively decrease lipid oxidation within 
the mitochondrial inner membrane. A lower DPPP-oxide fluorescence intensity following MitoQ 
treatment would indicate the involvement of mitochondrial membrane lipid oxidation.  
In comparison, a general lipid soluble antioxidant, vitamin E (α-tocopherol succinate; 
VEs), at both 10 µM and 25 µM, was used to estimate the involvement of total cellular lipid 
oxidation. A 10 mM VEs stock solution prepared in DMSO was filtered sterilized using DMSO 
safe tuffryn membrane (Acrodisc, #4433) and stored in smaller aliquots under an inert gas, N2 
atmosphere, at –80°C. The stock solution was subsequently diluted in RPMI 1640 media and added 
to culture. 
 
Mitochondrial membrane potential 
Following fatty acid pretreatment, cells were rinsed with PBS, incubated with 656 nM 
Rhd123 for 15 min at 33˚C in the dark, and washed twice with PBS. Cells were then analyzed for 
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rhodamine fluorescence by confocal microscopy.  The relative levels of Rhd123 fluorescence 
intensities were monitored at 488 nm (emission) and 530 nm (excitation) using confocal 
microscopy (Meridian Ultima).  A reduction of fluorescence intensity reflects the decrease of MP.    
 
Cytosolic ROS production 
To measure the change in cytosolic ROS production, e.g. H2O2, after n-3 PUFA and n-6 
PUFA pretreatment, 5 µM CMH2-DCFDA (5-(and-6)-chloromethyl-2', 7’- 
dichlorodihydrofluorescein diacetate acetyl ester) dissolved in DMSO was loaded into selected 
cultures for 10 minutes in the dark at 33˚C before imaging (19).  Cleavage of acetate moieties by 
esterases inside the cell causes the 2,7-dichlorofluorescein to be trapped inside the cell, rendering it 
available for oxidation by peroxides or hydroperoxides (81, 82).  ROS production was quantified 
based on the intensity of the oxidized fluorescent probe trapped within the cell. H2O2 (10 µM) 
served as a positive control to induce cytosolic ROS production. DCFDA was laser excited at 488 
nm and monitored with a 530 nm barrier filter. 
 
Fluorescence microscopy and quantification 
Laser excitation confocal microscopy (Meridian Ultima, Okemos, MI) was used to capture 
all images requiring quantification of fluorescence intensity. Cells loaded with fluorophores and 
washed with PBS were replenished with phenol-free Leibovitz media (Gibco, #21083-027) for 
image analysis. Leibovitz media contains pyruvate for cells to be sustained in a CO2 free 
environment temporarily. Excitation energy and emission filters were adjusted based on the 
property of each fluorescent probe. In addition, cells were observed for contamination and other 
artifacts using phase contrast microscope (Nikon) after each treatment.  Groups of cells (>5 cells) 
from at least fourteen fields for each sample were captured using laser excitation confocal 
microscopy (Meridian Ultima).  Average fluorescence intensities of all the pixels in the image of 
individual cells were captured to measure the mean brightness of each treatment. 
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Cell death detection assay 
Following fatty acid treatment, floating cells were harvested, washed, lysed and centrifuged 
at 13,600 x g to sediment nuclei and intact cells. Supernatants containing histone-complexed DNA 
fragments were collected for the quantification of late stage apoptosis using an ELISA (47).  
Absorbance and reference wavelengths were set at 405 nm and 490 nm, respectively. Values were 
normalized by the numbers of adherent cells from each dish. As a control for the mouse cell lines, 
cultures of cells were incubated for 24 h at a non-permissive (39˚C) temperature, in RPMI 1640 
media without γ-IFN supplementation. We have previously demonstrated that both non-permissive 
(39˚C) temperature and 5 mM butyrate incubation are capable of enhancing YAMC cell apoptosis 
(16, 69).   
 
Cytotoxicity study 
For maximum sensitivity, 1.4x104 YAMC cells per well were seeded into 96-well tissue 
culture dishes and incubated for 24 h with RPMI 1640 medium supplemented with γ-IFN.  Cells 
were incubated with culture medium containing the compound of interest, i.e. MitoQ, at 0-50 µM 
for 0- 72 h.  Supernatants were harvested, and the amount of LDH released was assayed by ELISA.  
LDH release was compared to untreated wells, which were lysed with 1% Triton-X 100, i.e. total 
releasable LDH present in untreated cells, according to the manufacturer’s instructions (Roche, 
cat#1644793). 
 
Statistical analysis 
For all lipid oxidation and cytosolic ROS production studies, the statistical tests were 
performed using contrast testing under linear mixed models (83).  Fixed effects were constructed to 
indicate the treatments under which the data points were generated.  Well level random effects 
were used to account for the dependency of wells within the same dish.  When one set of 
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experiments were conducted over a prolonged time frame, a factor accounting for the day to day 
variation was also added into the model.  
For all other studies, the effects of independent variables (main treatment effects) were 
assessed using SuperAnova.  A difference between means was tested using the least square means 
test.  A 95% level of probability was accepted as being statistically significant. 
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CHAPTER IV 
RESULTS 
DHA and butyrate synergistically enhance lipid oxidation 
Dose dependently, butyrate treatment over a 24 h period increased lipid oxidation in DHA 
(50 µM for 72 h) primed YAMC cultures (Fig. 4A, data are shown at the end of Chapter IV and in 
Appendix B).  DHA pretreated YAMC cells demonstrated an increase (p<0.05) in lipid oxidation 
after co-incubation with physiological levels of butyrate (1-10 mM).  However, in LA pretreated 
cultures, no trend was observed. DHA or LA treatment, in the absence of butyrate, did not increase 
lipid oxidation, compared to no fatty acid treatment.   
In select experiments, in which 5 mM butyrate treatment was carried out for 24 h, DHA 
primed cells showed a 29% increase in lipid oxidation (p=0.0013), when compared to no butyrate 
treatment (Fig. 4C).  The increase in oxidation was detected as early as 12 h following butyrate 
treatment in DHA primed cell (26%; p=0.0095) (Fig. 4B).  Specifically, lipid oxidation in response 
to butyrate (12 h) treatment was not different from the control, i.e., the no fatty acid pretreated 
cultures.  At 6 h, butyrate treatment was insufficient to induce a change in lipid oxidation in any of 
the fatty acid treatment groups.  Figures 4D and E are representative photomicrographs of YAMC 
cells illuminated following the oxidation of the DPPP fluorescence probe in cell membrane lipid 
bilayers.  Even though the difference in the induction of lipid oxidation with the addition of 24 h 
butyrate co-treatment was not significantly different between the two fatty acids (p< ½  t = 
0.0579), DHA pre-treated samples showed a two-fold greater induction of oxidation relative to the 
LA group (Fig. 4C). 
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    Fig. 4 . Effect of fatty acid and butyrate co-treatment on membrane lipid oxidation. Select YAMC cultures 
were incubated with butyrate (0-10 mM) for 12 or 24 h with BSA-complexed DHA or LA (50 µM) for 72 h. 
A) Butyrate dose dependently increased lipid oxidation in DHA primed cells.  In comparison, after co-
treatment with 5 mM sodium butyrate for the final B) 12 h or C) 24 h of fatty acid treatment, DHA primed 
cells consistently exhibited a greater increase in lipid oxidation (p<0.01), when compared to no butyrate 
treatment, whereas LA treatment did not show an effect. Lipid oxidation was measured by quantifying the 
fluorescence intensity of oxidized DPPP incorporated into cellular membranes. Shown are the means (± SE) 
of changes in average pixel intensities of all cells in each treatment group. The number of cells analyzed (n) 
ranged from 181 - 280, collected from 5 independent experiments. Values not sharing the same letters are 
significantly different (p<0.05). Panels D and E show representative photomicrographs (200 x) of DPPP 
loaded YAMC cells treated with DHA and LA, respectively, for 72 h and with 5 mM butyrate for the final 24 
h. 
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        Fig. 5A. Vitamin E succinate reduces butyrate-induced membrane lipid oxidation in YAMC cells. 
Cultures were treated with 50 µM BSA-complexed DHA, LA or with no fatty acid ± VEs (10 µM) for 72 h 
with or without butyrate (5 mM) for the final 24 h. Lipid oxidation induced by butyrate in DHA primed 
YAMC cultures was partially reversed by 10 µM VEs incubation. The number of cells analyzed (n) ranged 
from 46 -118, collected from 2 independent experiments. Values not sharing the same letters are significantly 
different (P<0.05). 
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    Fig. 5B. VEs (25 µM) appears to promote lipid oxidation in YAMC cells. The number of cells analyzed 
(n) ranged from 46 -118, collected from 2 independent experiments. Values not sharing the same letters are 
significantly different (P<0.05). 
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Effects of vitamin E succinate and MitoQ 
The data in Fig. 5A demonstrate that the accumulation of lipid oxidation induced by DHA and 
butyrate co-treatment for 24 h, were partially reversed by a lipid antioxidant, Vitamin E succinate (VEs) at 10 
µM (p<0.05).  A similar anti-lipid oxidation effect of VEs was also detected in cells co-treated with butyrate 
for 12 h (Appendix B: Table B1-3).  VEs did not affect the basal level of membrane oxidation in both LA-
treated and the control groups.  The effect of a higher dose of VEs (25 µM) was also evaluated, and appeared 
to promote lipid oxidation (Fig. 5B).  The results depicted in Fig. 6 suggest that the subcellular origin 
of oxidation induced by DHA and butyrate was localized to the mitochondrial lipid membrane 
bilayers.  Lipid oxidation induced by butyrate in DHA primed cells was blocked by a mitochondria 
targeted antioxidant, MitoQ (79).  MitoQ (p<0.05) at as low as 2.5-5.0 µM (Figures 6A-B) reduced 
DPPP oxidation following a 12 or 24 h co-incubation period with butyrate (5 mM).  In comparison, 
in LA treated cultures, MitoQ did not affect lipid oxidation.  MitoQ toxicity was evaluated by 
determining the percentage of lactate dehydrogenase (LDH) release in YAMC cultures over a 12 - 
24 h incubation period using 0 - 50 µM MitoQ.  MitoQ concentrations up to 10 µM did not perturb 
cell viability (Fig. 6C).  
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    Fig. 6. MitoQ prevents lipid oxidation induced by DHA and butyrate co-treatment. Select YAMC cultures 
treated with DHA (50 µM) showed an increase in lipid oxidation following 24 h butyrate (5 mM) co-
treatment. A) Lipid oxidation was reversed by MitoQ incubation in a dose dependent manner when MitoQ 
was loaded for the final 1 h of butyrate co-treatment. B) Following 24 h of co-incubation with butyrate, 
MitoQ (2.5 or 5 µM) reduced oxidation to basal levels. In LA (50 µM) treated cultures, no increase in lipid 
oxidation was observed initially. C) The level of LDH release induced by MitoQ incubation indicates a lack 
of cytotoxicity. YAMC cells were incubated with complete medium containing MitoQ at 0-50 µM, for one or 
24 h.  Supernatants were harvested, and the levels of LDH release were assayed, compared to an untreated 
well and expressed as percentages LDH present in cultures lysed with 1% Triton-X 100 (total releasable 
LDH). Data represent n=3 wells. For panels A and B, the number of cells analyzed (n) ranged from 283 - 
655, collected from 5 independent experiments. Values not sharing the same letters are significantly different 
(P<0.05). 
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Effects of fatty acids on mitochondrial MP and MPT  
 
 DHA incubation increased the basal level of MP in a dose dependent manner, whereas no 
effect was observed in LA treated cells (Fig. 7A).  Compared to LA, 72 h DHA treatment increased 
resting MP by 14% (p<0.01) (Fig. 7B).  This finding is consistent with previous observations (11) 
showing that DHA is capable of increasing resting MP.  
A reduction of fluorescence intensity reflects a decrease in MP (Fig. 8).  After 24 h 
butyrate co-incubation, the dissipation of MP was two fold greater in DHA (20%), compared to the 
LA (10%) treated cells (Fig. 8A).  Fig. 8B shows that CsA at 1 µM, loaded 30 min prior to butyrate 
incubation and replenished 12 h after the initial dose, blocked the dissipation of MP following 50 
µM DHA or LA treatment for 72 h with 5 mM butyrate co-incubation for the final 24 h.  Similarly, 
BkA at 1 µM inhibited MP dissipation induced by the same reagents and treatment (Fig. 8C).  
Comparable observations were made upon co-incubation with CsA or BkA with butyrate for the 
final 6 and 12 h.  The ability of CsA and BKA to prevent the dissipation of MP, a phenotypic event 
depicting the opening of MPT pores, indicates the activation of either a transient or a prolonged 
MPT (59). 
 
 
 
 
 
 
 
 
 
 
 
 
DHA  LA  
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Fig. 7. Mitochondrial membrane potential is enhanced by DHA in a dose dependent fashion in the 
absence of butyrate. A) YAMC cultures were treated with DHA or LA at 0, 10, 50, 100 and 200 µM for 72 h. 
To measure the changes in the basal level of mitochondrial membrane potential following fatty acid 
treatment, cells (post-treatment) were loaded with Rhodamine 123 (656 nM) for 15 min. Each treatment 
group contained 107 - 221 cells from 2 independent experiments. B) Representative photomicrographs 
(400X) of cells incubated with 50 µM DHA or LA for 72 h. DHA enriched cells demonstrated a higher 
fluorescence intensity as compared to LA. C) In another set of experiments (n=4), DHA incubation, 
compared to LA, at 50 µM increased resting membrane potential by 14% (P<0.0001). Mean (± SE) 
fluorescence values were from 4 wells from 2 independent experiments containing 1058 (DHA group) and 
847 (LA group) cells. Values not sharing the same letters are significantly different (P<0.05). 
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    Fig. 8. Effects of fatty acid treatment on mitochondrial membrane potential. A) MP was dissipated by 
butyrate (5 mM) co-incubation, for the final 6, 12 and 24 h, following 50 µM DHA or LA treatment for 72 h, 
in a time dependant manner. After 24 h butyrate co-incubation, the dissipation of MP was two-fold greater in 
the DHA (20%), compared to the LA (10%) treated cells. Mean (± SE) fluorescence values were collected 
from 4 wells from 2 independent experiments. The number of cells analyzed (n) ranged from 106 - 362. B) 
Cyclosporin A (CsA) at 1 µM, loaded 30 min prior to butyrate incubation and replenished 12 h after the 
initial dose, blocked the dissipation of MP following 50 µM DHA or LA treatment (72 h) with butyrate (5 
mM) co-incubation for the final 24 h.  C) Bongkrekic acid (BkA) at 1 µM inhibited MP dissipation induced 
by butyrate (5 mM) co-incubation for 24 h.  Similar observations were made upon co-incubation with CsA or 
BkA with butyrate for the final 6 and 12 h (data not shown).  Values not sharing the same letters are 
significantly different (P<0.05). 
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    Fig. 9. Selective targeting of a redox active antioxidant (MitoQ) to mitochondria does not block apoptosis 
induced by fatty acid and butyrate co-treatment as indicated by DNA fragmentation ELISA.  Cultures were 
incubated with 5 mM butyrate and 50 µM DHA or LA or no fatty acid as described in Fig. 3.  MitoQ at 2.5 
µM was loaded 30 min prior to butyrate incubation.  The apoptotic index represents optical density, obtained 
by ELISA described in Material and Methods, per the number of adherent cells in culture. The number of 
cultures analyzed (n) ranged from 9-12, collected from 3 independent experiments. Values not sharing the 
same letters are significantly different (P<0.05). 
 
 
 
Apoptosis phenotype 
DHA and LA treatments (72 h) differentially primed cells for apoptosis induced by 
butyrate or butyrate plus MitoQ co-treatment.  Using a Cell death ELISA (Roche), which measures 
DNA fragmentation (described in Materials and Methods), the effect of 24 h butyrate incubation to 
induce apoptosis in LA primed cells was significantly greater than in DHA primed cells (p=0.049).  
The result is in contrast to our other findings, which shows DHA and butyrate synergistically 
activate pro-apoptotic events.  However, the control treatment butyrate at 5 mM incubated for 24 h 
induced apoptosis [Fig. 9], which is consistent with a previously published study (47).  In addition, 
contrary to our hypothesis, this pro-apoptotic effect of butyrate was not blocked by MitoQ co-
incubation.  MitoQ co-incubation, which prevented lipid oxidation, did not block apoptosis induced 
by butyrate, in all treatments.  
0
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Cytosolic reactive oxygen species 
Using YAMC cell culture model, 5 mM butyrate treatment did not increase cytosolic ROS 
production, compared to no butyrate treated samples (Fig. 10). This observation is distinct from 
experiments using animal models (22, 30).  The sub-confluent YAMC cell cultures were treated 
with 50 µM BSA-complexed DHA, LA or with no fatty acid for 72 h with or without 6 - 24 h 
butyrate (5 mM) co-treatment.  The differences in the pair-wise comparison of ROS production 
between no butyrate and 5 mM butyrate treatments at the same incubation time and with the same 
fatty acid were obtained by comparing the average fluorescence intensity of YAMC cells loaded 
with CMH2-DCFDA (5 µM) for 15 min prior to imaging. 
Data collected to generate all of the observations above are summarized in tables 1 to 7 in 
the following pages. 
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Fig. 10. Pair-wise comparison of reactive oxygen species production between no butyrate and 5 mM 
butyrate treatment at the same incubation time, treated with the same fatty acid.  Cultures were treated with 
50 µM BSA-complexed DHA, LA or with no fatty acid for 72 h with or without a) 6, b) 12 or c) 24 h 
butyrate (5 mM) co-treatment. YAMC cells (post-treatment) were loaded with CMH2-DCFDA (5 uM) for 15 
min prior to imaging.  Mean (± SE) fluorescence values were collected from 4 wells from 2 independent 
experiments. The number of cells analyzed (n) ranged from 434-735. Values not sharing the same letters are 
significantly different (P<0.05). 
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CHAPTER V 
DISCUSSION AND SUMMARY  
 
The preferential incorporation of n-3 PUFA, including DHA (11, 17), into mitochondrial 
membrane phospholipids, i.e. cardiolipin, increases cell (membrane) susceptibility to damage by 
oxidative stress (18).  Data from our laboratory have suggested that mitochondria and ROS 
production mediate the apoptotic enhancing effect of butyrate and dietary fish oil in colonic crypts 
(7, 9, 19).  The current experiments support this hypothesis, since DHA, a major fatty acid found in 
fish oil, enhanced YAMC mitochondrial lipid oxidation induced by co-incubation with 
physiological concentrations (0 - 10 mM) of butyrate (Fig. 4).  It seems likely that the 
mitochondrial pool of phospholipid is the major site for lipid oxidation induced by butyrate and 
DHA, since the mitochondrial targeted lipid antioxidant, MitoQ, completely blocked the effect of 
butyrate (Fig. 6).  In comparison, VEs, a lipid soluble antioxidant (Fig. 5) attenuated but did not 
fully prevent lipid oxidation.  
The electrical potential across the inner membrane of mitochondria ranges between 150 
and 180 mV, negative inside and is the highest electrical potential difference across any membrane 
in a typical cell, making up 70 to 80 % of the mitochondrial electrochemical proton gradient (61).  
In the present study, we show that DHA pretreated YAMC cells exhibit a higher resting MP (Fig. 
7C), compared to LA.  In addition, DHA up to 200 µM dose dependently increased the resting 
level of MP (Fig. 7).  These findings suggest that incorporation of DHA into mitochondrial 
membranes induces changes in its bioenergetic properties: electron transport, ATP production, H+ 
permeability and MP, congruent with the report by Stillwell et al. (see (84) for review).  It appears 
likely that DHA incorporation (and LA to a lesser extent) increased the function of the proton 
pump within the respiratory chain.  The respiratory chain is coupled to the extrusion of protons 
from the mitochondrial matrix generates a proton gradient on the both sides of the inner 
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mitochondrial membrane.  This proton gradient makes up part of ∆P (proton motive force), which 
is the driving force for ATP synthesis through ATP synthase. It is also the driving force for the 
uptake of various cationic molecules such as Ca++ (61).   Therefore, the elevated MP associated 
with increasing DHA concentration is consistent with a fundamental shift in the activity of the 
respiratory chain.  
An increase in mitochondrial bioenergetics is the result of increased ATP production and 
oxygen consumption (54, 57, 61).  Under normal conditions, i.e., mild oxidative stress 
environments, a high ATP/ADP ratio inhibits the rate-limiting step, cytochrome-C oxidase activity 
through a feedback loop and causes a regulated mitochondrial respiratory rate.  This is an 
established mechanism within the mitochondria to prevent ROS hyper-production (54).  In 
comparison, the mild uncoupling effect of uncoupling proteins, e.g. UCP, to dissipate ∆P by 
permitting a controlled leakage of protons across the mitochondria membrane, allows electron 
transport to occur without the constraint of ATP utilization in some cells (54).  Studies have shown 
that free fatty acids are capable of uncoupling energy production in isolated mitochondria. 
Unsaturated fatty acid incorporation could increase membrane permeability for H+ while increasing 
resting state respiration (84, 85).  Nevertheless, the potency of this long chain PUFA to collapse 
MP decreased with increasing carbon chain length (85).  DHA incorporation into living cells may 
increase respiratory chain action through its mild protonophoric action, to sustain a prolonged 
respiratory chain activation while maintaining an elevated resting level of MP as shown in Fig. 7.  
Consistent findings have been reported in other studies demonstrating that MP in DHA-enriched 
cells was higher relative to control groups treated with EPA, LA, arachidonic acid and oleic acid 
(11).    
A population of cells exhibiting an increased MP should produce more cellular oxidants 
(85).  Using the YAMC cell model, our data show that lipid oxidation in cells treated with 50 µM 
DHA or LA was not different from the control, in the absence of butyrate (Fig. 4A).  Moreover, 
cytosolic ROS was not increased in all treatments with or without butyrate co-incubation (Fig. 9) as 
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compared to the no fatty acid treatment (control) group.  Nevertheless, upon butyrate co-incubation 
for 24 h, DHA primed cells demonstrated a greater level of lipid oxidation compared to LA and no 
fatty acid group (Fig. 4C).  These data suggest that DHA sensitizes or primes cells to subsequent 
oxidative stress events.  
Since a more negative membrane surface potential, i.e., a greater MP, has been correlated 
to an increase in the respiration rate (57) and DHA incorporation, which may favor PT pore 
opening (59), it is likely that DHA treatment primes cells for apoptosis via a mitochondrial PTP 
dependant mechanism.  
Malis et al.  (18) showed that the incorporation of PUFA into mitochondrial membrane 
phospholipids sensitizes cells towards the activation of apoptosis by Ca++.  Ca++ is a well-known 
signaling messenger implied in MPT activation.  An increase in intracellular free Ca++ 
concentration is in most cases followed by an increase in the mitochondrial free Ca++ concentration, 
of which the Ca++ uniporter is believed to be one of the channels for Ca++ uptake (52, 61).  Ca++ 
overloading has been shown to activate PT pore opening and has been correlated to ROS stress 
induction (52, 53, 61, 86).  Furthermore, Ca++ uptake into the mitochondrial matrix may be driven 
by MP (61).  A cytosolic Ca++ surge and subsequent mitochondrial Ca++ overload would eventually 
reach a threshold level of Ca++ to trigger MPT, resulting in MP dissipation (86).  This is consistent 
with the effect of DHA in the absence of butyrate, where DHA dose-dependently increased resting 
MP levels, while LA treatment at identical concentrations did not (Fig. 4).   
On the other hand, studies have shown that butyrate treatment, which is capable of 
increasing intracellular ROS stress (36, 37), also triggers the accumulation of endogenous Ca++ 
within the intracellular compartment (87).  It is known that supraphysiological concentration of 
Ca++ suffice to induce PT, while lower doses facilitate the induction of PT by other stimuli (57).  
The increase in the resting level of MP by DHA and release of intracellular Ca++ into the 
intracellular compartment by butyrate may facilitate a more effective uptake of Ca++ into 
mitochondrial matrix.  This is noteworthy, because as a ligand, Ca++ binds to VDAC-ANT-
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Cyclophilin D complex of the mitochondrial PTP, whereby it activates MPT (57).   
Ca++ accumulation within the mitochondrial compartment has been shown to trigger the 
release of PUFA enriched at the sn-2 position of phospholipids in mitochondrial membranes (18).  
Therefore, when cells are treated with butyrate and DHA together, these short and long chain fatty 
acids may induce Ca++ overloading, which has been correlated to the uncoupling effect and the 
ability to induce MPT of free fatty acid.  It is likely that these sequential alterations result in the 
perturbation of mitochondrial membrane and induce a mitochondrial-dependant apoptosis. 
Oxidative damage of mitochondrial membrane proteins and phospholipids (49) can directly 
trigger MPT (53).  We have demonstrated that DHA and butyrate dissipate MP that is preventable 
by CsA and BKA.  It is possible that MPT is involved in the mechanism by which DHA and 
butyrate protect against colon cancer development.  Literature review suggested oxidative stress 
accumulation within mitochondria activates MPT and is a self-amplifying process, meaning that 
several consequences of an oxidative reaction may feed forward to amplify MPT activation and 
ROS hyper-production within cells (57).  Focusing on a single mitochondrion level, cardiolipin, a 
unique mitochondrial phospholipid localized primarily within the inner membrane, is needed for 
the activity of enzyme complexes involved in electron transport such as cytochrome-C oxidase and 
NADH reductase (11).  The incorporation of DHA into of cardiolipin following dietary fish oil 
supplementation favors oxidative stress accumulation and apoptosis induction.  Specifically, ROS 
production is correlated to the unsaturation index of cardiolipin acyl chains (9, 11).  Moreover, the 
oxidation of the cardiolipin acyl chains is associated to the release of cytochrome-C from 
mitochondria triggering caspase activation (49, 68) an event inhibited by α-tocopherol, resveratrol, 
and Bcl-xl protein expression (49, 88).  Furthermore, cardiolipin oxidation and subsequent 
cytochrome-C release are correlated to MP depolarization (52, 66), ROS generation (49) and MPT-
regulated apoptosis (89).  On the other hand, redox metabolism, caspases, amphipathic peptides 
and Bcl-2 family proteins have been shown to act on mitochondria to induce MPT.  Further 
research is required in order to elucidate whether these pathways are involved in the DHA and 
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butyrate induced MPT activation.  
The oxidation of PUFA yields α,β-unsaturated enals, e.g., malodealdehyde (MDA), 
acrolein (Acr), crotonaldehyde (Cro), t-4-hydroxy-2-nonenal (HNE), and 4-oxo-2-nonenal (26, 28).  
These enals differentially react with deoxyguanine to form cyclic DNA adducts  (an indicator of 
DNA lesion) or with protein to covalently modify the function within cells (28, 90). Interestingly, 
oxidized n-3 PUFA as opposed to the native unoxidized n-3 PUFA, are capable of inducing a 
PPAR-α mediated anti-inflammatory effect (90).  With regards to the efficacy of a specific type of 
PUFA, DHA has been found to be the most efficient precursor for DNA adducts formation in some 
cell lines, when compared to other PUFA with lower numbers of double bonds (26).  Specifically, 
the formation of DNA adduct is proportional to the number of double bonds of its PUFA 
precursors (26).  It is likely that n-3 PUFA incorporation into mitochondrial membranes provides 
substrate for lipid oxidation (91) and increases the generation of aldehydes (enals), which are pro-
apoptotic.  
Concomitant with a role of ROS in the activation of apoptosis, the inhibition of ROS 
production by Bcl-2 and Bcl-xL is associated with their anti-apoptotic roles (92, 93).  Interestingly, 
butyrate and n-3 PUFA have been found to decrease Bcl-2 expression in colon cancer cell lines 
(94) and in rat colonic crypts (67), respectively.  In comparison, Bax protein (proapoptotic) 
increases the membrane unsaturation index, especially in cardiolipin, which promotes membrane 
lipid oxidation (88).  Furthermore, this pro-apoptotic effect of Bax is enhanced in cells primed with 
polyunsaturated fatty acids.  This evidence in its entirety suggests that DHA or n-3 PUFA exposure 
may increase oxidative stress and damage, hence priming cells for apoptosis induction by butyrate.  
This may explain why DHA and butyrate synergistically enhance apoptosis in the colon (7, 22, 30). 
Other than Ca++ overload and oxidative stress accumulation, a variety of different pro-
apoptotic signal-transduction pathways may be involved in the activation of apoptosis induced by 
DHA and butyrate.  For instance, butyrate incubation may activate apoptosis via a Fas 
receptor/Fas-L dependant pathway (47), which is an extrinsic pathway that may not involve the 
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function of mitochondria.  This may explain why MitoQ, which blocked lipid oxidation induced by 
butyrate in DHA primed cells (Fig. 3), did not block apoptosis (Fig. 6), compared to the control 
treated with fatty acid only.  Alleva et al. has shown that coenzymeQ could block biochemical but 
not the apoptotic pathway that is Fas receptor-mediated (95).    
It has also been noted that the endoplasmic reticulum (ER) can induce apoptosis 
independent (96) or dependent of mitochondria (97).  Relative to mitochondria, the ER exhibits 
similar membrane potential maintenance properties and the ability to regulate Ca++ homeostasis, 
and may therefore play a pivotal role in ROS production and subsequent apoptotic events.  The 
involvement of ER in the regulation/activation of apoptosis in colonocytes needs further 
investigation. 
Figure 11 illustrates the putative mechanisms by which the incorporation of DHA into 
mitochondrial membrane phospholipids results in an increase in MP.  Intracellular events related to 
mitochondrial function are activated subsequent to butyrate treatment.   
 
Significance  
Collectively, these data further elucidate the apoptotic cellular targets that are modulated by 
DHA and butyrate in colonocytes, i.e. by eating a diet high in dietary fish oil and fermentable fiber.  
We propose that n-3 PUFA alter colonocyte mitochondrial membrane composition and function, 
thereby creating a permissive environment for apoptosis induced by subsequent pro-apoptotic 
agents, such as butyrate.  Using non-malignant transformed immortalized YAMC, we tested our 
overall hypothesis that metabolically-induced (butyrate) stress, the result of membrane lipid 
oxidation and disrupts mitochondria function.  We demonstrate for the first time that mitochondrial 
lipid oxidation was induced by DHA and butyrate co-incubation in living cells.  In conclusion, 
dietary fish oil and pectin may prevent colon cancer tumorigenesis by modulating mitochondrial 
membranes lipid oxidation and function. 
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    Fig. 11. i) Putative mechanisms by which the incorporation of DHA into mitochondrial membrane
phospholipids results in an increase in membrane potential.  ii) Intracellular events related to
mitochondrial function are activated subsequent to butyrate treatment.  The findings from this study 
show that mitochondrial membrane lipid oxidation and MPT activation are two events likely to be
involved in the activation of cell death induced by DHA and butyrate co-treatment.  
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APPENDIX A 
EXPERIMENTAL PROTOCOLS 
 
Protocol # A-1 Preparation of a complete RPMI 1640 media for YAMC culture 
 
Purpose: To prepare a complete RPMI 1640 media for YAMC cell culture. 
 
Reagents (supplier, catalog number), (storage) 
 500 ml (one bottle) RPMI 1640 without Glutamine (Mediatech, #15-040-CV), (walk in 
freezer) 
 26.6 ml Fetal Bovine Serum (Hyclone, # AK 12434), (chest freezer) 
 5.3 ml Glutamax™ (Gibco, 35050-061), (chest freezer) 
 0.532 ml ITS “-” (Collaborative Biomed. Products, #4351 “-”), (P.H. fridge) 
___ ITS “-”reconstitution: add 5 ml sterile distilled water into lyophilized powder. 1 ml 
of reconstituted solution is sufficient to supplement one 
liter of medium (0.1% dilution). 
1. ___ Thaw FBS and Glutamax™ in the fridge several hours in advance or overnight.  
2. ___ Add FBS, Glutamax™ and ITS “-” into 500 ml RPMI 1640 medium.  
3. ___ Label bottle as “complete” media and store it at 4˚C. 
 
Final volume: 531.9 ml 
Final concentrations: 5% Fetal Bovine Serum, 1% Glutamax™, 0.1% ITS “-”:   
Linoleic acid 0 
Insulin  5 µg/ ml 
Transferin  5 µg/ ml 
Selenious acid  5 ng/ ml 
 
The following reagent is to be added fresh into the media before use: 
 5 units γ-IFN (Gibco BRL, #13284-021, stored in -80˚C freezer) per 1 ml complete RPMI 1640 
media.  
 
1. ___ For each 10 ml complete RPMI 1640 medium, supplement 1µl γ-IFN. 
 
 
_____________________________________________ 
 
Protocol # A-2 Preparation of YAMC cell culture 
 
Purpose: To start a culture by growing cells in a T-75 flask. 
 
Preparation: 
 In warm water bath (37 ˚C), warm tap distilled water in a clean beaker for 30 min. 
 Turn on the UV in the hood ~15 min prior to using the hood. 
 
Procedure: 
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1. ___ Warm prepared complete RPMI 1640 media to RT. 
2. ___ Remove a vial of YAMC cells from the liquid nitrogen storage system and thaw it in the 
pre-warmed water immediately.  
3. ___  Add thawed cells into ~10 ml media in a 15 ml conical tube. 
4. ___  Spin down YAMC at 200 x g (1096 rpm: tabletop centrifuge in room 307) for 5 
min at 6 Acc./Dcc.  
5. ___  Aspirate supernatant to remove freezing media.  
6. ___  Resuspend pellet in 20 ml complete RPMI 1640 media with 2 µl of γ-IFN. 
7. ___  Add cells/media into a T-75 flask. 
8. ___  Incubate cell culture at 33˚C under 5% CO2 atm. 
 
Two-days after: 
9. ___ Feed cells every 2 (maximum 3) days by aspiring old media and by replenishing cells with 
fresh RPMI 1640 media with γ-IFN. 
10. ___ When culture reaches 70-90% confluence, passage cell culture through trypsinization 
(refer to Appendix A: Protocol # A-3 YAMC Cell Culture). 
 
 
 
______________________________________________ 
 
Protocol # A-3 YAMC Cell Culture: Seeding, Passing or Freezing 
 
Purpose: To pass and to seed or freeze YAMC cell culture. 
 
Preparation: 
 Warm complete RPMI 1640 and trypsin-EDTA (Gibco, #25300-054) to RT. 
 
Procedure:  
For any ~80% confluent cell culture in a T-75 flask: 
1. ___ Aspirate old media, rinse monolayer of cells with ~10ml HBSS (Sigma, H-6648) without 
disturbing the cell monolayer. 
2. ___ Aspirate HBSS. Add 5 ml Trypsin-EDTA and incubate cells at 33 ˚C until > 90% cells are 
lifted. 
3. ___ Check cells under microscope. Gently tapping on the side of the flask to loosen adherent 
cells. 
4. ___ Add cells in suspension into a 50 ml conical tube containing ~15 ml complete RPMI 1640 
medium. 
5. ___ Spin at 200 x g (1096 rpm, countertop centrifuge in room 307) for 5 min to remove 
trypsin in the media. Aspirate supernatant without disturbing the pellet. 
6. ___ Lightly flick the bottom of the tube to loosen the cells from the bottom of the conical tube. 
 
7. A. To seed cells in a culture dish:  
 Resuspend pellet in 4 ml of complete RPMI 1640 medium. 
Count cell (sterility is not critical):  
 Transfer ~ ½ ml of the homogenized cells in suspension into a 1 ml micro-centrifuge 
tube. 
 Transfer 5 µl of the cell suspension into a 500 µl micro-centrifuge tube. 
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 Add 5 µl trypan blue, 40 µl PBS into the micro-centrifuge tube. Mix well to yield a 
homogenized 10% suspension. 
 Transfer ~30 µl of the cell suspension onto a hemacytometer.  
 Count cell:  Cell density (cells count per ml) = Living cells count x 10^4 x 10 
# Squares counted  
 Seed cell according to desired density.  
 
B. To continue growing more cells in a T-75 flask: 
 Divide cell suspension (sterile) at 1:5 ratio. Aliquot each portion into 20 ml media with 
γ-IFN. Seed cells into a T-75 flask. 
 
C. To freeze (to store) cells in liquid nitrogen. 
 Resuspend cells in 4 ml of freezing media (EmbryoMax, # S-002-D). 
 Load each cryo vial with 1.0 - 1.5 ml cell suspension. Allow room for expansion. 
(Yield ~1 million cells per vial).  
 Keep vials in Mr. Freezer (Nalgene, #5100-0001) at –80˚C for a day (at most two days 
over the weekend) before transfering vials into liquid nitrogen for storage. 
 Record rack, box and coordinate of storage location into log book. 
 
8. Label vial/flask with name, date, passage number and cell type.  
 
 
___________________________________________ 
 
Protocol # A-4: Fatty acid-BSA complex 
 
Purpose: To prepare 2.5 mM fatty acid and bovine serum albumin (BSA) complex. 
 
Preparation: 
 2 screw caps and baked items (a spatula, a 100 ml beaker, two 4 ml glass conical vials). 
___ Bake glassware and spatula wrapped in foil and taped with autoclave tape at 180˚C for 4 h 
 
Materials: 
 FA-free BSA (BM, #100069), MW: 68000 
 Na2CO3 (JTBaker, #3604-01), MW: 105.99 
 RPMI 1640 medium (Mediatech, #150400LV) 
 Sterile distilled water (Baxter, 2F7115) 
 Others: filters (0.2 µm, tuffryn membrane), syringes, and icebox. 
 Fatty acid stocks in ethanol (stored under N2 at -80˚C): 
Recorded density and date of fatty acid stocks: 
Example: DHA [10.837                 µg/µl in EtOH], (2-01-02) 
  LA     [11.022                µg/µl in EtOH], (8-13-01)  
 
Procedure: 
1. ___ Aliquot ~40 ml of RPMI 1640 and 10 ml of sterile distilled water in a sterile hood. 
2. ___ Keep stocks on ice before and after vortex stock FA-EtOH vigorously.  
3. ___ Add 10 mg of FA (dissolved in EtOH) into 2 ml conical glass vial, respectively. 
Flush tubes with N2 before returning stocks to –80˚C for storage.     
  Example: need  922.76                  µl DHA [10.837 µg/µl]   
  907.28                  µl  LA [11.022 µg/µl]   
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4. ___ Clean needle with organic solvent. Dry down the FA with low stream of N2. 
 
5. ___ Make 0.05 M Na2CO3 while the FA-EtOH is drying. 
  Example:  53    mg Na2CO3 in 10          ml sterile H2O (need ~2 ml per FA-BSA) 
 
5. ___ Make 15% BSA solution. 
 Add 20             ml of RPMI 1640 medium into a 100 ml beaker.   
 Gently layer 3         g of BSA onto the medium.   
 Do not stir but let the BSA powder slowly dissolve down to the medium. 
 
6. ___ After dry down the FA,  
 Add 2 ml of 0.05 M Na2CO3 to each FA vial.   
 Flush the vial with N2 before vortex extensively.   
 Sit the vials at RT for 1 h. Vortex the vials several times to aid FA dissolve completely. 
 
7. ___ Calculate the materials needed to make 2.5 mM FA-BSA complex at FA/BSA: 3/1 
molar ratio. 
Example: DHA (MW: 328.5): 10 mg in 2 ml 0.05M Na2CO3;  
  BSA (MW: 68000): 15% Solution 
 
 Calculate the volume of 15% BSA solution needed for 10 mg DHA to obtain FA/BSA: 3/1 
mole ratio. 
        0.01 g DHA     x   1  x 68000 (BSA MW) x  100  = 4.6 (ml) 
  328.5 (DHA MW)      3         15          
 Calculate the total volume of solution needed for 10 mg DHA to make 2.5 mM DHA-BSA 
complex. 
  10 (mg of DHA)/ 328.5 (DHA MW.)/ 2.5 (mM) = 0.012177 (L) = 12.177 ml 
 
 Calculate the volume of basal RPMI medium needed for making the 2.5 mM DHA-BSA 
complex. 
  12.177 (total volume) - 2 (FA in 0.05M Na2CO3) - 4.6 (15% BSA) = 5.577  
 
 Î DHA 15% BSA RPMI  2.5mM DHA-BSA  
  2 ml      4.6 ml 5.577 ml Æ  12.177 ml 
 
**It’s difficult to completely retrieve the 2 ml FA-Na2CO3 from the glass vial. Therefore, 
take only 95% of everything to make the DHA-BSA complex. 
 
  1.9 ml DHA + 4.37 ml 15 % BSA + 5.298 ml RPMI. 
 
___ Apply similar calculation to LA. 
 
8. ___ Add the following volume of FA-Na2CO3, 15 % BSA, and RPMI to 15 ml conical tubes. 
 FA-Na2CO3 15 % BSA RPMI  FA-BSA 
 DHA 1.9       4.37  5.30  11.57 
 LA 1.9       5.12  6.53  13.55 
  
9. ___ Flush tubes with N2.  Shake them on a belly dancer for 0.5 ~ 1 h at RT. 
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10. ___ Use 0.2 µm tuffryn membrane to filter sterilize FA-BSA complex in a cell culture sterile hood.  
Aliquot the complex. 
 
11. ___ Store aliquots protected from light at –20 °C. Retain for only 1 month. 
 
 
________________________________________________ 
 
Protocol # A-5 YAMC Cell Culture: Fatty acids, Butyrate and other Treatments 
Ref: Fan et al. Am J Physiol (1999) 
   
Purpose: To treat YAMC cells with butyrate and different polyunsaturated fatty acids. 
 
Pre-preparation: 
 Recover cells from liquid nitrogen (refer to Protocol # A-2) 
Sources: User: _______ Passage: _____ Rack: ____ Box#: ___ R&C: _______ 
 Grow cells in a T-75 flask in complete RPMI 1640 medium with γ-IFN.   
 Allow >24 h for cells to adhere and to recover from trypsinization. 
 
Day 1: (for experiment using chambered cover glass) 
1. ___ Treat 2 wells chambered cover glasses (Nalge Nunc Intl, # 155380): 1 ml media per well. 
 Thaw. Filter sterilizes FBS with 0.2 µm tuffryn membrane (Acrodisc, #4192). 
 Prepare 20 % FBS in RPMI 1640 media (always make 2~3 ml extra).  
 Calculation (example):  2 ml FBS + 8 ml Media ---> 10 ml Media/FBS 
 Load 1 ml media/FBS per well.  
 Incubate for ≤ 4 h or overnight at 33 ˚C. 
 
Day 2:  
2. ___ Warm complete RPMI 1640 to RT. 
3. ___ Trypsinize and seed cells (refer to Protocol # A-3)  
4. ___ Seed YAMC at 7,000 cells/well in a 2-well chambered cover glass. 
  ____ # chambered slides needed. 
  ____ml cells/RPMI media + ___µl γ-IFN (at 1µl per 10 ml media) 
5. ___ In a conical tube: add together calculated volume of cell/media and fresh media with γ-
IFN. Gently invert to mix. 
6. ___ Add 1 ml cells/ml (pipette to homogenize) into each pretreated well; incubate at 33 ˚C 
under 5 % CO2 atm. 
 
Day 3, 4 and 5: [Note: cells should have recovered from trypsinization.] 
 
7. ___ Treat cells with 50 µM fatty acids.  
 Check if vitamin E treatment is required. The treatment starts on Day3 and last for 72 h, 
refer to Media Preparation for details. 
 Defrost FA-BSA stock [2.5 mM]. 
*FA stock should be prepared and used within a month and should be stored at –20˚C.  
 Prepare 50 µM fatty acids with complete RPMI 1640. 
Calculation: (0.02 ml stock + 0.98 ml Media     ----> 1 ml FA/media) 
                   ____ ml stock + ___  ml Media    -----> ___ ml FA/media 
*Make fresh FA solution everyday and do not store left over FA stock. 
 Add γ-IFN (1 µl per 10 ml FA/RPMI 1640 media). 
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(An additional step for Day 5):  
___ Butyrate co-treatment 
 Prepare 1 ml 500 mM Butyrate stock in a tube wrapped in foil to protect butyrate stock 
from light. Refer to Media Preparation. 
 Start 5 mM butyrate treatment by gently pipetting in 10 µl of 500 mM butyrate during the 
designated time.   Ref: Fan et al. Am J Physiol (1999) 
 Gently pipette with a 1000P pipette to mix evenly.  
 
□ Check if any of the following treatments is involved on day 5. Refer to Media Preparation for 
the following treatments. 
 
□ MitoQ  □ Cyclosporin A (CsA)  □ Bongkrekic acid (BKA)    
 
A sample timetable: estimated butyrate treatment, dye loading and assay time  
(** Modify timetable accordingly based on experimental design) 
Incubation time (h)/ 
butyrate treatment 
Butyrate 
loading time  
Dye loading 
time  
Assay time Note 
+ But     6 
 - But     
+ But     12 
- But     
+ But     24 
- But     
** During planning, expect to spend 7~10 min on imaging per dish. 
** Start dye loading for the next dish at ~3 min prior to the finishing of the previous one. 
 
Day 6: Imaging Day (Analysis is done in the Imaging Analysis lab in vet school) 
Preparation: 
 Warm Leibovitz buffer (Gibco, #21083-027) & RPMI 1640 media to RT (<2 h) before start. 
 Bring the following to Image Analysis Lab.  
 a) In an ice chest with blue ice: fluorescence probes and 500 mM butyrate (and isobutyrate, 
when applicable).  
b) In a case at RT: Fluorescence probe in media, Leibovitz buffer, complete RPMI 1640 
with γ-IFN, PBS, gloves, timer, pipettes. 
c) In a warm case: Cell culture covered in foil. In the case, keep a flask of warm water to 
maintain a warm environment for the cells and a thermometer to gauge 
the change of temperature during transfer. 
  
8. ___ Dye and inhibitors/control loading: 
Refer to protocol  #5: Lipid oxidation analysis using DPPP. 
  #6: Mitochondrial membrane potential analysis using Rhodamine 123. 
  #7: Cytosolic oxidation analysis using CMH2-DCFDA. 
 
Media preparation [Otherwise stated, all “media” refers to complete RPMI 1640] 
5 mM (final concentration, i.e. f.c.) Butyrate (Acros, #263190050) 
___ Stock preparation: **protect from light and use within 4 h.  
 500 mM butyrate stock: weigh out and dissolve 55 mg sodium butyrate in 1 ml 
media. 
 Filter sterilize stock using a 0.2 µm tuffryn membrane (Acrodisc, #4192).  
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___ Load 10 µl butyrate [500 mM] stock per 1 ml YAMC cell/media.  
 
5 mM (f.c.) Isobutyrate (Sigma, # I-1754)   Ref: Heerdt et al. Cancer Res (1994) 
___ Stock preparation: 
 500 mM isobutyrate stock: pipette 44 µl isobutyrate in 1 ml media. 
 Filter sterilizes stock using a 0.2 µm tuffryn membrane (Acrodisc, #4192).  
___ Load 10 µl isobutyrate [500 mM] stock per 1 ml YAMC cell/media. 
 
10 µM (f.c.) Vitamin E Succinate (MW= 530.8) (Sigma, #95255) (DMSO (v/v%) = 0.1%) 
___ Stock preparation: 
 10 mM (VEs): dissolve 53.08 mg in 10 ml DMSO (Sigma, # D8418) 
 Filter sterilize 10 ml stock solution (Acrodisc, #4433) and make 1 ml aliquots.                       
 Flush vials with N2 and store aliquots in -80˚C.  
___ Load 1 µl VEs [10 mM] stock per 1 ml YAMC cell/media.  
 
0, 2.5, 5 µM (f.c.) Mito Q (MW= 665.65)   Ref: Kelso et al J Biol Chem (2001)  
Stock in storage: 50 mM Mito Q/DMSO stored in inert gas: Argon environment, in dark 
___ Working stock solution preparations: 
 
Calculation: a)   50 mM(x)    = (0.5 ml) 0.5 mM 
             x  = 0.005 ml 
 0.5 mM (10 µl) = (1 ml ) (5 µM) 
b) 0.5 mM (100 µl)  = (200 µl) (0.25 mM) 
0.25 mM (10 µl)  = (1 ml ) (2.5 µM) 
___ Mito Q [f.c.= 5 µM]: 
 Load 5 µl MitoQ [50 mM] stock per 495 µl media to yield 0.5 ml Mito Q [500 µM]. 
 Load 10 µl MitoQ [50 mM] stock per 990 µl media to yield 1 ml Mito Q [5 µM]. 
 
___ Mito Q [f.c.=2.5µM]: 
 Load 100 µl Mito Q [0.5 mM] stock per 100 µl media to yield 200 µl Mito Q [0.25 mM]. 
 Load 10 µl Mito Q [0.25 mM] stock per 990 µl media to yield 1 ml Mito Q [2.5 µM]. 
 
1 µM Cyclosporin A (CsA) (Calbiochem, #239835) 
___ Stock preparation: 
 10 mM stock solution: Add 0.8315 ml Ethanol per 100 mg CsA. (aliquot and store stock 
solution at -80˚C) 
 1 mM CsA working solution: Add 900 µl DMSO per 100 µl CsA [10 mM: stock]  
 100 µM CsA in Media: Add 900 µl Media per 100 µl CsA [1 mM: working stock] 
 Filter sterilizes using a 0.2 µm DMSO safe membrane (Acrodisc, #4433). 
 
___ 30 min prior to butyrate loading, load 10 µl (100 µM) CsA per 1 ml cell/media. 
___ For CsA txt >12 h, without aspirate old media, add another 10 µl CsA into each well at 12 h. 
Pipette to mix.   Ref: Dr Tjalkens; Bradham et al. Mol.& Cell Biol. (1998) 
 
1 µM Bongkrekic acid (BkA) (MW=486.6) (Sigma, #B6179, in solution) 
___ (100x) Stock preparation: 
 (For treatment requiring butyrate co-loading, prepare butyrate 
[500 mM] in advance). 
 Load 48.66 µl BKA per 1 ml media (or media with 500 mM 
butyrate, for co-loading). 
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___ Load 10 µl of the stock into each well with ~1 ml YAMC cell/media.  
___ Pipette to mix evenly. 
 
_________________________________________________ 
 
Protocol # A-6 YAMC Cell Culture: Diphenyl-1-pyrenylphosphine (DPPP) Loading and 
Control Treatments 
Ref: Takahashi et al. Free Radic Biol Med (2001)  
 
Purpose: To study lipid oxidation using DPPP, lipid soluble fluorescents probe. 
 
Cell culture: refer to Protocol # A-4 
 
5 µM (f.c.) DPPP (Molecular Probes #D-7894) (MeOH: 0.0096%; DMSO: 0.096%) 
___ Stock preparation: 
 4.7 mM DPPP: dissolve 5 mg DPPP in solvents: 250 µl MeOH + 2.5 ml DMSO, aliquot at 
100 µl and store in –20˚C for up to a month. 
 Or, thaw a 100 µl aliquot. 
 Vortex vigorously until all pellets dissolved. 
 5 µM DPPP: add 53 µl DPPP [4.7 mM] in 50 ml PBS. 
1. ___ Aspirate old media from each well.  
2. ___ Gently, rinse cells once with PBS. 
3. ___ Load 1 ml DPPP/PBS [5 µM] into each well. 
4. ___ Incubate at RT, protected from light, for 10 min. 
5. ___ Wash twice with 1 ml PBS before adding 1 ml fresh Leibovitz buffer for imaging.   
 
For control treatments only: 
10 µM (f.c.) H2O2 (Sigma, #H1009) 
___ Prepare DPPP [5 µM] working solution in advance. 
___ Stock preparation: 
 50 mM H2O2: 5.67 µl H2O2 (30%) per 1 ml distilled H2O.  
 Calculation (example):  X (50 mM) = (5 ml) (10 µM)  
  X= 1 µl  
 Add 1 µl H2O2 [50 mM] into 5 ml DPPP/PBS [5 µM] for co-loading. 
1. ___ Aspirate old media from each well.  
2. ___ Wash each well with 1 ml PBS. 
3. ___ Load 1 ml solution into each emptied well. 
4. ___ Incubate at RT, protected from light, for 10 min. 
5. ___ Wash twice with 1 ml PBS before adding 1 ml fresh Leibovitz buffer for imaging. 
 
25 µM (f.c.) Cumene hydroperoxide (Sigma, #C-0524) (EtOH: 0.048%) 
___ Stock preparation: 
 100 mM CumOOH: 18.6 µl CumOOH per 1 ml solvent: 500 µl 95%EtOH and 500 µl 
dH2O.  
 Flush the bottle of reagent with Argon gas. Store it in dark at 2-4˚C. 
 Calculation (example):  X (100 mM) = (5 ml) (25 µM)  
      X  = 1.25 µl  
 Add 1.25 µl CumOOH (100 mM) into 5 ml DPPP/PBS [5 µM] for co-loading. 
1. ___ Aspirate old media from each well.  
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2. ___ Wash each well with 1 ml PBS. 
3. ___ Load 1 ml solution into each emptied well. 
4. ___ Incubate at RT, protected from light, for 10 min. 
5. ___ Wash twice with PBS before adding 1 ml fresh Leibovitz buffer for imaging. 
 
Fluorescence Microscopy Imaging 
___ Monitor fluorescence intensities at 351 nm (excitation) and 380 nm (emission) using 
confocal microscopy (Meridian Ultima). 
 
 
____________________________________________ 
 
Protocol # A-7 YAMC Cell Culture: Rhodamine 123 Loading and Inhibitor Treatments 
Ref: Scaduto Jr, et al. Biophysical J (1999); Fan et al. Am J Physiol (1999) 
 
Purpose: To study mitochondrial membrane potential using Rhodamine 123 (Rhd 123). 
 
656 nM (f.c.) Rhd 123 (Molecular Probes, #R-302) 
___ Stock preparation: 
 Prepare 13.12 mM Rhd 123: dissolve 5 mg Rhd 123 in 1 ml MeOH), aliquot at 100 µl and 
store in –20 ˚C for up to a month.  
Or, thaw a 100 µl aliquot.  
 Prepare 656 nM working solution: 
Calculation (example): (x) (13.12 mM)= (50 ml) (656 nM)  
X= 2.5 µl 
 Add 2.5 µl Rhd 123 [13.12 mM] per 50 ml of media.     
 
1. ___  Aspirate old media from each well. 
2. ___ Gently, rinse cells once with PBS. 
3. ___ Load 1 ml (656 nM) Rhd 123 per well. 
4. ___ Incubate at 33 ˚C protected from light for 15 min. 
5. ___ Gently, wash cells with PBS before adding 1 ml fresh Leibovitz buffer (Gibco, #21083-
027) for imaging. 
 
Inhibitors: 
1 µM Cyclosporin A (CsA) (Calbiochem, #239835) 
___ Stock preparation: 
 10 mM stock solution: add 0.8315 ml Ethanol per 100 mg CsA (aliquot and store stock 
solution at –80 ˚C ). 
 1 mM CsA working solution: add 900 µL DMSO per 100 µl CsA [10 mM: stock]  
 100 µM CsA in Media: add 900 µL Media per 100 µl CsA [1 mM: working stock] 
 Filter sterilize using a 0.2 µm DMSO safe membrane (Acrodisc, # 4433). 
 
___ 30 min prior to butyrate loading, load 10 µl (100 µM) CsA per 1 ml cell/media 
___ For CsA txt >12 h: Without aspirate old media, add another 10 µl CsA into each well at 12 h. 
Pipette to mix.   Ref: Dr Tjalkens; Bradham et al. Mol.& Cell Biol. (1998) 
 
1 µM Bongkrekic acid (BKA) (MW=486.6) (Sigma, #B6179, in solution) 
___ (100x) Stock preparation: 
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 (For treatment requiring butyrate co-loading, prepare butyrate 
[500 mM] in advance). 
 Load 48.66 µl BKA per 1 ml media (or media with 500 mM 
butyrate, for co-loading) 
 
___ Load 10 µl stock per well with ~1 ml YAMC cell/media.  
___ Pipette to mix evenly. 
 
Fluorescence Microscopy Imaging 
___ Monitor fluorescence intensities at 488 nm (emission) and 530 nm (excitation) using confocal 
microscopy (Meridian Ultima). 
 
 
___________________________________________ 
 
 
Protocol # A-8 YAMC Cell Culture: CMH2-DCFDA Loading and Control Treatments 
Ref: Scaduto Jr, et al. Biophysical J (1999); Barhoumi et al. Fundam Appl Toxicol (1996). 
 
Purpose: To study cytosolic reactive oxygen species production using CMH2-DCFDA  
[5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate acetyl ester]  
 
5 µM (f.c.) CMH2-DCFDA  (Molecular probes, #C-6827) 
___ Stock preparation: 
 Prepare 5 mM CMH2-DCFDA: 50 µg into 18 µl DMSO 
 Carefully pipette up and down to mix 
Calculation (example): (x) (5 mM) = (50 ml) (5 µM)   
X= 50 µl 
 Add 50 µl (5 mM) per 50 µl of media. 
 
1. ___  Aspirate old media from each well. 
2. ___ Gently, rinse cells once with PBS. 
3. ___ Load 1 ml (5 mM) CMH2-DCFDA per well. 
4. ___ Incubate at 33 ˚C protected from light, for 15 min. 
5. ___ Gently, wash cells with PBS before adding 1 ml fresh Leibovitz buffer for imaging. 
 
Control treatments only: 
10 µM (f.c.) H2O2 (Sigma, #H1009) 
___ Stock preparation: 
 50 mM H2O2: 5.67 µl H2O2 (30%) per 1 ml distilled H2O  
Calculation (example): X (50 mM) = (5 ml) (10 µM)  
X= 1 µl  
 Add 1 µl H2O2 [50 mM] per 5 ml PBS.  
 
1. ___ Aspirate old media from each well.  
2. ___ Wash each well with 1 ml PBS. 
3. ___ Load 1 ml solution into each emptied well. 
4. ___ Incubate for 10 min prior to dye loading. 
 
25 µM (f.c.) Cumene hydroperoxide (Sigma, #C-0524) (EtOH: 0.048%) 
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___ Stock preparation:  
 100 mM CumOOH: 18.6 µl CumOOH per 1 ml solvent: 500 µl 95%EtOH and 500 µl 
dH2O.  
 Flush the bottle of reagent with Argon gas. Store it in dark at 4 ˚C.  
Calculation (example): X (100 mM) = (5 ml) (25 µM)  
X  = 1.25 µl  
 Add 1.25 µl CumOOH (100 mM) into 5 ml PBS. 
 
1. ___ Aspirate old media from each well.  
2. ___ Wash each well with 1 ml PBS. 
3. ___ Load 1 ml solution into each empty well. 
4. ___ Incubate for 10 min prior to dye loading. 
 
Fluorescence Microscopy Imaging 
___ Monitor fluorescence intensities at 488 nm (emission) and 530 nm (excitation) using confocal 
microscopy (Meridian Ultima). 
 
 
__________________________________________ 
 
 
Protocol # A-9 Cell Death Detection ELISA, Plus 
Source: Roche, # 1774425  
Ref: Fan et al. Am J Physiol (1999) 
 
Purpose: To quantify apoptosis/histone-complexed-DNA fragments of floating YAMC cells and 
to normalize values to the number of adherent cells from the same culture dish. 
 
Cell culture: 
___ Seed 25,000 cells per 35 mm cell-culture-dish, 24 h prior to fatty acid treatment. 
___ Refer to Protocol # A-4 for fatty acid, butyrate and other treatments. 
___ Note: load only 1.5 ml total volume per dish on the last day of FA treatment. 
 
Preparation:  
__ Label 2 ml epi-tubes (2 sets): floater collection (step 1) & total cell counting.  
1.5 ml epi-tubes: supernatant collection (step 11). 
__ Reconstitute working solutions: 
 Dissolve substances in bottle 1,2 and 3 in 450 µl ddH2O for 10 min and mix evenly. 
Bottle 1: anti-histone-biotin 
Bottle 2: anti-DNA-peroxidase   (store at 2-8°C for upto 2 months) 
Bottle 3: positive control 
 
 ABTS tablets from bottle 7: one tablet/5 ml substrate buffer (bottle 6).  
**Store reconstituted ABTS protected from light for up to a month at 2-8°C. 
 
__ Warm complete RPMI 1640 media and trypsin-EDTA to RT. 
 
Assay Procedures: 
Supernatant preparation (35 mm dish): (in room 307) 
1. ___ Swirl dish to gather floaters. Collect all (1.5 ml) media with floaters in a 2 ml epi-tube.  
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(Replenish each dish of adherent cells with 1 ml PBS and keep plates at 33˚C. These cells 
will be counted within the next 3hs, see Cell Counting). 
2. ___ Centrifuge floaters/media at 5,000 rpm (Eppendorf centrifuge) for 5 min at RT. 
3. ___ Remove supernatant manually using a pipette without disturbing the pellet.  
4. ___ Wash: resuspend pellet in 1 ml media (without γ-IFN). 
5. ___ Centrifuge at 5,000 rpm (Eppendorf centrifuge) for 5 min at RT. 
6. ___ Resuspend cell pellet in 125 µl lysis buffer (bottle 5). 
7. ___ Lyse: mix thoroughly and incubate samples for 30 min at 4°C. 
 
At the same time (in lab 321),  
8. ___ Prepare immunoreagent, volume: 1/20 anti-DNA-POD, 1/20 anti-histone-biotin, 18/20 
incubation buffer. [need 80 µl per sample] 
9. ___ Prepare an ice-chest with ice. 
10. ___ After 30 min incubation (step 7), centrifuge lysate at max speed (13,600 x g, Eppendorf 
centrifuge) for 10 min, at 4°C. 
11. ___ Prepare a template and a microtiterplate (MP; with enough wells) to include all samples, 
controls and a blank. Set up the spectrometer to read at 405 nm (reference wavelength at 
490 nm) from designated wells.  
12. ___ Keep centrifuged lysate on ice, while transferring 100 µl of the supernatant carefully into 
an epi-tube (1.5 ml) without shaking the pellet.  
 
 
 
ELISA procedures: 
13. ___ Transfer 20 µl of all samples (include histone-DNA complex, bottle 3) into the middle of 
the MP well. 
14. ___ Add to each well 80 µl of the immunoreagent using multiple channel pipette. 
15. ___ Cover the MP with an adhesive cover and a foil. Incubate on a MP shaker under gently 
shaking (300 rpm) for 2 h at RT. 
16. ___ Tape both sides of the modules to secure them. Remove solution thoroughly by inverting 
and tapping it on a piece of paper towel. 
17. ___ Rinse each well (3 x) with 250 µl Incubation buffer (bottle 4). Remove solution carefully 
by tapping. 
18. ___ Lights off. Pipette into each well 100 µl ABTS solution. 
19. ___ Incubate on a plate shaker at 250 rpm until the color development is sufficient for a 
photometric analysis. (~10 min, but check after 5 min of incubation). 
20. ___ Measure the optical density at wavelength set (step 11) against ABTS solution as a blank. 
 
Cell Counting: 
For each sample from a 35 mm dish: 
1. ___ Swirl dish to agitate and to remove non-adherent cells remaining. Aspirate off PBS. 
2. ___ Load 0.5 ml trypsin-EDTA into each 35 mm dish containing adherent cells. 
3. ___ Incubate at 37˚C for 3 min. 
4. ___ Terminate trypsinization by loading 1 ml complete RPMI 1640 media into each dish. 
5. ___  Tap and swirl plate lightly. Collect all lifted cells in 1.5 ml epi-tube. 
6. ___ Count cells using a hemacytometer. 
 
 
 
________________________________________________________ 
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Protocol # A-10 LDH Activity Assay for Adherent YAMC Cell Culture 
Source: Roche, #1644793 Cytotoxicity-Detection Kit (LDH)    
 
Purpose: To measure the cytotoxicity of a reagent on adherent YAMC cultures following a 24 h 
incubation period. 
 
Cell culture/Assay preparation: 
 All samples and controls should have an n>3. Prepare a 96-well template to include all samples 
and controls. 
 Wash cells in complete RPMI 1640 medium. Dilute cell density to [~1.4x104 cells/100µl 
complete RPMI 1640 media] for optimal sensitivity. 
 Add 100 µl cell-suspension per well in a sterile 96-well tissue culture plate except for wells 
designated for background control, substance control I and substance control II. 
 Incubate cells overnight (>24 h) at 33˚C for cells to recover from trypsinization. 
 
Day 1 Preparation: 
 Prepare complete RPMI medium with γ-IFN. 
 Prepare (2 x) solution of several concentrations of test substance (e.g. cytotoxic agents) in 
medium by serial dilution (will add 100 µl medium to a final vol. of 200 µl/well)  
 
Procedures: 
1. ___ Samples: 
 Aspirate old medium and floating cells from wells. Add 100 µl fresh media with γ-IFN into 
each well. 
 Transfer 100 µl of the test substance dilutions into corresponding wells containing adherent 
cells.  
2. ___ Low control: add 100 µl medium (without test substance) to each of the triplicate wells 
containing 100 µl/well cells. 
3. ___ High control: add 100 µl Triton-x-100 (Sigma, x-100) solutions (2% in RPMI 1640, filter 
sterilized) to each of the triplicate wells containing 100 µl/well cells. 
4. ___ Background control: fill 200 µl medium into each of the triplicate wells without cells. 
5. ___ Substance control I: add 100 µl substance (maximum concentration used in the 
experiment) to triplicate of wells containing 100 µl/well medium without cell. 
6. ___ Substance control II: load 50 µl test substance + 50 µl LDH standard + 100 µl medium 
to triplicate of wells without cell. 
7. ___ Incubate cells in a (33 °C, 90% humidity, 5% CO2) incubator for 24 h. 
 
Day 2 Assay: 
8. ___ Use a multi-channel pipette, transfer 100 µl/well supernatant carefully from the culture 
plate into corresponding wells of an optically clear 96 well flat bottom MP. 
9. ___ Add 100 µl reaction mixture to each well and incubate for ~30 min at RT, in dark. 
10. ___ Set ELISA reader to measure absorbency at 490 nm (reference wavelength: 650 nm). 
11. ___ Read. 
 
___________________________________________ 
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Protocol # A-11 Image Analysis field selection 
 
Purpose: To show the field of cells analyzed to facilitate statistical analysis and data interpretation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mean = Average (average integrated intensity) of 
all cells in each well 
well 
Well # =2 
dish 
8-10 fields per well were imaged. Cell 
number per field is highly dependent on 
each experiment and/or treatment. ranges 
6 ~ 200 cells per well 
= one cell (or area)
=> Average intergrated intensity (per pixel)
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Figure 1 
??? 
Figure 3 Figure 2 
Protocol # A-12 Criteria for cell selection 
 
Purpose: To set up the criteria for cell (boundary of a cell) selection for all assays involving image 
analysis using the Meridian Instrument system. 
 
Include: 
a) only a WHOLE CELL. The keys are “whole” (see, Exclude, “c”) and “cell”. Make sure an area 
selected is a cell and use palette options, e.g., hue-lum to justify cell boundary.   
 
Exclude: 
a) Any cell with an odd shape. 
It is possible to have contamination of cell type. Select only epithelial cells, which are of research 
interest. 
 
b) Any cell with an odd size.  
Within each screen, select areas of similar sizes. Exclude those that are too big or too small. Refer 
to Figure 1 (below).  
 
c) Any cell that < 90% of its area is within the screen. Refer to Figure 2. 
 
d) Actively dividing cell.  
These cells show different properties compared to the non-dividing cell. They are normally very 
bright regardless of treatment. 
 
e) Two neighboring cells that do not show clear edges or boundaries. Splitting the two cells 
subjectively may alter the average integrated values. Refer to Figure 3. 
 
f) When in doubt (exclude the cell)! 
 
 
 
 
_______________________________________________ 
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Protocol # A-13 Protein Extraction and Western Blotting 
 
Purpose: To extract cytosolic and mitochondrial protein for protein assay or western blotting. 
 
Protein extraction preparation:  
 Prepare an ice-chest with ice.  
 Turn on and cool down eppendorf microfuge to 4˚C. 
 
Buffer Preparations: 
To make 250 ml Stock Mito buffer: (final concentration, i.e. f.c.) 0.3 M sucrose (Sigma, S9378)/ 1 
mM EDTA (Sigma, ED4SS)/ 5 mM Hepes (Sigma, H4034), pH 7.4 
1. ___ Weigh and add 596 mg Hepes into ~10 ml dH2O. Adjust pH to 7.4 with 10 M NaOH. 
2. ___ Add 51.4 g sucrose, 190 mg Na4EDTA. 
3. ___ Bring up to 250 ml with dH2O. Store at -20˚C in 10 ml aliquots.  
 
 Complete mito buffer: 
1. ___ Thaw a 10 ml aliquot of mito buffer stock. 
2. ___ Add 0.4 ml protease inhibitor cocktail (Sigma, p8340),  
3. ___ Add 5 mg DTT (Sigma, D0632) to each 10 ml aliquot to make 3 mM DTT (f.c.). 
 
To make 20 ml Stock RIPA buffer: (f.c.) 50 mM Tris-HCl (Fisher, BP153-500), pH 7.4, 0.5% 
deoxycholate (Sigma, D6750), 1% NP-40 (Sigma, N6507), 0.1% SDS (Fisher, BP166-100), 50 µM 
NaF (Sigma, S6521) (Note: use made up 0.4 M NaF stock from Lauire) 
1. ___ Dissolve 157.6 mg Tris-HCl in dH2O, add dH2O up to 20 ml   
2. ___ add 0.1 g deoxycholate 
3. ___ add 0.2 ml NP-40 
4. ___ add 0.02 g SDS 
5. ___  add 2.5 µl (0.4 M) NaF stock from Laurie 
6. ___  store at -20˚C in 1.2 ml and 1.5 ml aliquots  
 
 complete RIPA buffer:  
1. ___  Immediately before use, dissolve 1 tablet mini protease inhibitor (Roche, 1836153) in 1.5 
ml stock RIPA buffer. 
2. ___ Add 171.6 µl (of 1.5 ml RIPA with protease inhibitor) in 1.2 ml stock RIPA buffer.  
 
Procedure: 
1. ___ Spin down YAMC cells at 200 x g for 5 min. 
2. ___ Wash pellet with PBS (~5 ml), spin at 200 x g for 5 min (Repeat x2). 
3. ___ Aspirate supernatant and resuspend pellet with 500 µl complete mito buffer.  
** Keep everything on ice from this step on.    
4. ___ Pass through 27 gauge needle, 3 times.   
5. ___ Centrifuge at 600 x g for 10 min at 4˚C in microcentrifuge. 
6. ___ Transfer supernatant to 1.5 ml epi-tube and discard nuclei pellet (and unlysed cells) 
7. ___ Centrifuge supernatant at 15,000 x g for 10 min at 4 ˚C. 
8. ___ Transfer supernatant (cytosol) to a new 1.5 ml epi-tube. Save pellet (mitochondria). 
 
Cytosolic fraction:  
1. ___ Mix, aliquot supernatant into 30 µl each and store at -20 ˚C. 
 
Mitochondrial fraction: 
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1. ___ Resuspend mitochondria pellet into 100 µl RIPA buffer. 
2. ___ Pass it through 29 gauge needle and sit it on ice 20-30 min. Label 500 µl tubes. 
3. ___ Centrifuge at 12,000  x g for 10 min to remove unsolubilized material 
4. ___ Transfer supernatant (solubilized mitochondrial perparation) to new 1.5 ml epi-tube 
5. ___ Mix and make 11 µl aliquots. Store at -20˚C. 
 
6. ___ Save aliquots of complete mitochondrial buffer and RIPA buffer for protein assay. 
 
     
***************************** 
Western blotting 
 
Day 1-Preparation:  
 Thaw samples in a ice chest with ice.  Label 0.6 ml epi-tubes. 
 Prepare western template sheet.  
 Transfer membrane (Immobilon-P, Invitrogen, LC2005-2) 
 
1. ___ Pipette samples, H2O, 5 x pyronin into 0.6 ml epi-tubes (final volume <35 µl/well). Mix by 
gentle inversion. Quick spin in a table-top centrifuge.  
2. ___ Heat at 98˚C, 5 min (or 10 min, if sample >20 µl). Quick spin to collect condensation. 
3. ___ Remove tape and comb off the gel cassette. Mark lane with a marker for visibility for 
sample loading. Align 3rd grid with lower gasket and clamp unit. (For one gel, put a 
alumine plate to block other side). 
4. ___ Add “running buffer” into space between gels and into basin. 
5. ___ Load samples (use 10 µl tips, helps to prevent bubble accumulation in the well).  
6. ___ Lid on. Bring the unit into 4˚C cold room. Connect electrodes to power supply (red to red, 
black to black). Run at 45 mAmp (1 gel) or 90 mAmp (2 gels) for 1 h. 
* When dye front nears bottom of gel, turn off power supply, set current to 0, and unplug unit. 
 
7. ___ Pour “transfer buffer” into a clean staining tray. 
8. ___ Return “running buffer” from unit into original bottle for re-use (*fresh running buffer runs 
faster). 
9. ___ Place gel case on bench, large side down. Crack it open with a spatula along the seam. 
10. ___ To mark lane, cut the corner above the 1st lane of gel. Cut gel away from case from the 
thick bottom lip. Carefully transfer gel to staining tray containing transfer buffer. 
11. ___ Set up transfer cassette in large staining tray: black side down, thick sponge on bottom. 
Immerse cassette and sponge in transfer buffer. 
12. ___ Wet 6 mm filter paper with transfer buffer, top with a thick sponge in landscape 
orientation. 
13. ___ Place gel (quickly) onto filter paper, lane 1 on the right for the protein to end up on left 
side of membrane. 
14. ___ Wet transfer membrane with methanol (use dry gloves and tweezers to avoid nonspecific 
blotching). Layer it onto gel. Prevent bubbles getting between the layers, especially 
between gel and membrane. 
15. ___ Wet another filter paper with transfer buffer. Layer it onto membrane. Use test tube to 
gently roll out bubbles. 
16. ___ Place thin sponge onto filter paper. Roll out bubbles. Close cassette. 
17. ___ Insert cassette into transfer unit (black side faces labeled “black”, hinges face up). 
18. ___ Put stir bar into bottom of transfer unit. Fill unit with transfer buffer. Bang unit to get rid of 
bubbles. Stir on stir plate in 4˚C cold room.  
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19. ___ Run unit at constant current 400 mAmp for 75 min (max 90 min, for bigger proteins). 
 
While transferring: 
20. ___ Prepare 4% nonfat dry milk (Carnation)/PBS/Tween in a 50 ml tube (1.2 g/30 ml 
PBS/Tween). 
21. ___ After transfer, move cassette to a large tray. Open cassette. Clip off the top right corner of 
membrane to mark the first lane. 
22. ___ Flip membrane with tweezers for the protein side to face up. Rinse and quick shake in 
PBS/T. Replace PBS/T with 4 % nonfat milk/PBS/T. Shake gently for 1 h at RT. 
 
Optional: Stain gel by immersing gel in Coomassie Staining solution (reusable) on a shaker for 1 h 
at RT. Rinse and de-stain with de-staining solution by shaking vigorously. Change de-staining 
solution every 15 min for as many times as needed. Look for any blue band or non-transferred 
protein. 
 
23. ___ Return “transfer buffer” from unit into original bottle for re-use. 
24. ___ Prepare 4% nonfat milk/PBS/T (0.8 g/20 ml PBS/Tween). Immediately before adding 
transfer membrane, add 1˚Ab. Mix gently. The membrane should always face up. 
25. ___ Transfer membrane into 1˚Ab. Shake gently in 4˚C cold room overnight. 
 
Day 2 
26. ___ Transfer membrane into tray with PBS/T for brief wash 
27. ___ Pour out PBS/T, add fresh PBS/T to tray. Shake vigorously for 10 min. Repeat once. 
28. ___ Prepare 4% nonfat milk/PBS/T in a 50 ml tube and pour into small tray. Immediately 
before immersing membrane, add 2˚Ab. Mix gently. 
29. ___ Transfer membrane into 2˚ Ab, shake gently at RT for 1 h. 
30. ___ Transfer membrane into a tray with PBS/T for a brief wash. 
31. ___ Pour off PBS/T and add fresh PBS/T to wash. Shake vigorously for 15 min. Repeat. 
32. ___ Mix Chemiluminescent Super Signal reagents A and B (0.5 ml each) into a 1.5 ml epi-tube. 
Mix by gentle inversion. 
33. ___ Using a pair of tweezers, place membrane in a folded acetate sheet, with protein side facing 
up. 
34. ___ Pipette reagent mixture from step 32 onto membrane. Gently lower acetate sheet to cover 
membrane with reagent mixture. 
35. ___ Incubate for 5 min at RT. 
36. ___ Transfer membrane to another new acetate sheet. 
37. ___ Immediately, read chemiluminescence on Fluor S-machine in room 435. 
 
In room 435: 
38. ___ Open machine doors (top and bottom). Ensure camera is set at 1.4 aperture for maximum 
light exposure. 
39. ___ Software instructions: choose Quality One under file. Open a “new file” and select function 
“Fluor-S”. Click on Select, Blotting chemiluminescent, and High Resolution.  
40. ___ Focus (at lower aperture, if too bright). Click once on the focus button until you hear 
camera clicks. With a piece of paper with visible text, adjust focus on the camera.  
41. ___ To properly position the membrane, make sure the numerical aperture is set at 1.4, close 
camera door (top). Next, click on position until you hear the camera clicks. Position 
membrane. 
42. ___ Acquire for 1 sec to warm up camera. Refocus if necessary. Acquire image for up to 5 min 
(gradual increase). 
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43. ___ On a pop up window, press and hold “Apple” and “B”, and check “invert display” and 
“autoscale” 
44. ___ Save file and/or export in tif format. 
 
 
________________________________________________________ 
 
Protocol # A-14 Dual labeling of apoptotic/necrotic YAMC using  
Annexin-V FITC & Propidium Iodide (PI) 
Ref: Fan et al Am J Physiol (1999) 
 
Purpose: To quantify early and late apoptotic events in YAMC cultures; immunofluorescense 
technique(47).       
 
*Caution: Sodium Azide and PI are poisonous and hazardous substances. Handle with care and 
dispose of properly. 
 
Reagents/Materials:     
 Annexin-V-FITC/PI Kit (Biosource, # PHN 1018): 
-Annexin V/FITC buffer saline: 1% BSA, 0.1% Sodium Azide, pH7.4 
-PI: 50 µg/ml PBS  
-Annexin Binding Buffer (1x): 10 mM HEPES/NaOH, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4 
 PBS (sterile) (Invitrogen, 14190-B6) 
 RPMI Media (Mediatech #  150400LV) with γ-IFN   
 Sterile H2O     
 Sterile100 mm dish for cell culture   
 5 mM Butyrate (Acros, #263190050) 
___ Dissolve 55 mg sodium butyrate in 1 ml RPMI media Î [500 mM] Sodium butyrate 
stock 
___ Filter sterilize (0.2µm, tuffryn membrane-REF4192) 
___ Load 10 µl [500 mM] butyrate per 1 ml YAMC cell/media 
    
Preparation: 
 Seed 100k YAMC cells in a 100 mm diameter dish (Falcon, # 353803) to grow for 72 h. 
 Treat or induce apoptosis in cells with different treatments (e.g. 5 mM butyrate treatment) 
 
Day of experiment~  
 Tube 1: Dilute 10x Annexin-V binding buffer 1:10 in sterile distilled H2O (10 µl in 90 µl).  
 Tube 2: Mix 1x Binding buffer with AnnexinV/FITC and PI buffers (5 µl Annexin-V/FITC 
and 10 µl PI per 100 µl binding buffer) ***protect from light.  
 Warm binding buffers and RPMI complete media (need ~6 ml per dish) in 37˚C water bath. 
 Turn on fluorescence microscope and make sure the system is working before beginning. 
 
Procedure: 
A) Floating cells:  
1. ___  Collect old media with floating cells in a sterile 15 ml tube. 
2. ___  Wash monolayer of cell with 6 ml sterile PBS. Collect sample into the same tube.   
** Incubate adherent cell (for counting) in RPMI complete media/γ-IFN at 33˚C while 
working on floating cells  
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3. ___  Sediment floaters at > 200 x g (need review) for 5 min. Carefully pipette to remove 
supernatant. 
4. ___  Wash pellet in PBS (~6 ml). Repeat #3.   
5. ___  Remove supernatant (~30 µl left). Gently tap to release cells. Resuspend pellet with 90 µl 
of Tube 2 (Biosource suggest: 2-3x10^6 cells/ml of tube 2) 
6. ___  Remove ~ 40 µl of the mixture to count cell using hemacytometer. 
i) Without further delay,  
___ Resuspend (~ 50 µl “floaters” left) with 200 µl binding buffer from tube 1.  
 ___ Incubate at RT for 15 min in the dark. (Work on 2nd tube while waiting) 
ii) Mix well. Drop ~ 40 µl of sample mixture on a microscope slide and cover with a 
cover slip, 24 x 60 mm. Invert slide before mounting it on the stage.  
iii) Set magnification power at (10 x 20) X. Use fluorescence microscopy to capture 5 
fields per slide, 3 images per field: phase contrast, FITC and TX-Red filters.  
iv) Overlay images. Count positively stained cells and total cell per image. 
 
B) Adherent cells only (-ve control): 
1. ___  Aspirate old media. 
2. ___  Wash cells with 6 ml sterile HBSS. 
3. ___  Trypsinize adherent cells with 6 ml trypsin for 3 minutes. 
4. ___  Resuspend cells with 12 ml complete media to stop reaction. 
5. ___  Transfer cell to a 50 ml falcon tubes & centrifuge at 200 x g for 5 min. 
6. ___  Repeat step A) 5 & A) 6. 
 
 
______________________________________________________________ 
 
Protocol # A-15 Agilant anti-active caspase-3 cell fluorescence assay 
Ref: Turner et al Can Lett (2002) 
 
Purpose: To quantify apoptosis by active-caspase-3 immunostaining technique. 
 
Preparation: 
 YAMC cell growing and apoptosis induction, e.g. 
Positive control: 39°C w/o γ-IFN, 72 h, floaters only 
Negative control: 33°C w/ γ-IFN, adherent cells only 
Treatment control: 33°C w/ γ-IFN, 6 h H2O2 (150 µM), adherent and floaters  
Test sample #1: 33°C, 72 h DHA (50 µM) + 24 h Butyrate (5 mM), adherent and floaters 
Test sample #2: 33°C, 72 h LA (50 µM) + 24 h Butyrate (5 mM), adherent and floaters 
 
Stock preparations:  
A: Staining buffer (s.b.) 
B: 1.5 µl SYT016 per 1 ml s.b..   [need: ____ml s.b, + ___ µl SYT016] 
C: 5 µg anti-caspase-3 (BD #559565) per 1 ml BD perm/wash solution. 
[need: ___ml soln + ___ µg Ab] 
D: 5 µg Cy5-conj. goat anti-mouse (Jackson IR #111-176-045) per 1 ml s.b.  
     [need ___ml s.b. + ___ µg Ab] 
E: BD Cyto-fix/Cyto-perm buffer (diluted in dH2O) (BD, 554715)  [need ____ ml] 
F: 1x BD perm/wash solution (dilute 10x in dH2O) (BD, 554715) [(1x) needed ____ ml] 
  
Procedure: 
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1. ___ Harvest, count and resuspend cells at 5x105/ml. Transfer 1 ml into a 2 ml epi-tube. 
2. ___ Adjust cell density to 1x106cells/ml in stock B (0.5 ml stock B for 5x105 cells). 
3. ___ Incubate for 10 min, at 33°C.  
4. ___ Wash cells in 2 ml s.b. and centrifuge at 200x g for 5 min. 
5. ___ Resuspend 5x105 cells in 250 µl stock E.  
6. ___ Incubate for 20 min, at 4°C (in the fridge). 
7. ___ Wash in 2 ml stock F. Centrifuge. 
8. ___ Add 50 µl stock C: 1°Ab (to 5 x 105 cells). 
9. ___ Incubate on ice, 20-30 min. 
10. ___ Wash cells in 2 ml s.b.. Centrifuge. 
11. ___ Add 50 µl stock D: 2°Ab.  
12. ___ Incubate on ice, 30 min, in dark. 
13. ___ Wash cells in 2 ml s.b. 
  
Instrument set up: 
 Set Bioanalyzer (Agilent 2100) up for cell assay: insert pressure cartridge; set chip selector at 
position 2. 
 
Sample loading: 
1. ___ Centrifuge cells (200x g) to remove s.b. 
2. ___ Dilute pellet with cell buffer (green) to 5x105cells/250 µl. 
3. ___ Check visually to make sure no cell clumps or agglomerates left. Pipett up and down to 
make sure cells are in suspension before loading. 
4. ___ Load 10 µl of the chip priming solution (white) into the large priming well (PS). Wait for 
60 sec for capillary force to fill all channels of the chip.  
 
**Essential practices: To prevent the introduction of air bubbles: 
Insert tip of the pipette to the bottom & center of the well when dispensing. 
Use inverse pipetting: push slightly over the first resistant when filling; empty the pipette tip 
only to the first resistance. 
 
** Protect dye solution from light.  
5. ___ Load 10 µl of focusing dye solution (yellow) into the focusing well (FD) to adjust the 
bioanalyzer optics for each individual chip. 
6. ___ Load 30 µl of cell buffer (green) into wash of the 2 cell buffer wells (CB). 
7. ___ Homogenize sample through piptetting. Load 10 µl per sample well. 
** Do not leave any well empty or the pressure cartridge may become clogged. Pipette 10 
µl of cell buffer or a sample replicate into any empty sample well. 
8. ___ Loaded chip must be read in bioanalyzer within 5 min. 
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Appendix B: EXPERIMENTAL RESULTS  
TABLE OF CONTENTS 
Table #  
B-1  Lipid Oxidation Induced by Fatty Acid Treatments and the Inhibitory Effect of VEs at 10 
and 25 µm  
 
B-2 Numbers of Analyzed Cells (n) per Treatment Group for Each Lipid-Oxidation Study 
B-3 Fluorescence Intensities and Numbers of Analyzed Cells (n) per Treatment Group in a 
Butyrate Dose Response Study  
 
B-4 Percent Change in DPPP-Oxide Intensity Following 5 mM Butyrate Co-Incubation  
B-5 Differences and Statistical Significance in the Induction of Lipid Oxidation Following     
Butyrate Co-Treatment Among Different Fatty Acid Treatment Groups 
  
B-6 SAS-Least Square Means Analysis: ROS Data – Pooled Dates (8/11 & 9/1/04)  
 
B-7 Summary of Fatty Acid and Butyrate Treatment Effects  
 
B-8  Outline of Research Proposal  
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Table B-1 Lipid oxidation induced by fatty acid treatments and the anti lipid-oxidation effect 
of Vitamin E at 10 and 25 µM (figure 1&2) 
No butyrate 5 mM butyrate Butyrate 
incubation (h) 
Vit E 
(µM)  
Fatty acids 
1 Fluorescence 
intensity 
2 Standard Error Fluorescence 
intensity 
Standard Error 
12 0 DHA 546 38 689 38 
12 0 LA 603 37 670 37 
12 0 No FA 516 37 629 37 
24 0 DHA 638 37 821 37 
24 0 LA 687 37 751 37 
24 0 No FA 595 37 692 37 
       
12 10 DHA 597 84 605 86 
12 10 LA 610 86 617 86 
12 10 No FA 606 86 610 86 
24 10 DHA 638 86 687 86 
24 10 LA 688 86 662 86 
24 10 No FA 664 84 633 81 
       
12 25 DHA 474 55 495 59 
12 25 LA 636 55 578 49 
12 25 No FA 340 51 464 161 
24 25 DHA 869 53 1006 54 
24 25 LA 1027 47 1150 45 
24 25 No FA 639 45 926 48 
1Values represent least squares means with (n) found in Table B-2, which is from 5 experiments. 
  
Table B-2 The number of analyzed cells (n) per treatment group for each lipid-oxidation 
study  
Date well/txt Treatment VEs No FA LA DHA 
 
 
Butyrate Incubation  12 h 24 h 12 h 24 h 12 h 24 h 
2002.10.18 2 Control   99 91 84 69 77 72 
  5 mM butyrate  76 100 73 42 63 67 
         
2002.11.15 4 Control  25 19 23 22 23 20 
  5 mM butyrate  21 23 21 21 22 21 
         
2003.01.30 2 Control  16 12 12 12 16 12 
  5 mM butyrate  14 12 14 13 12 12 
         
2003.02.10 2 Control - 14 12 13 14 12 12 
(10 µM Vit E)  + 12 13 12 13 13 12 
  5 mM butyrate - 12 12 12 12 13 12 
  + 12 14 12 12 12 12 
         
2003.02.21 2 Control  - 126 96 96 85 96 109 
(25 µM Vit E)  + 63 117 40 89 43 50 
  5 mM butyrate - 137 98 110 93 103 117 
  + 82 77 64 106 34 46 
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Total 
12 Control - 280 230 228 202 224 225 
  + 75 130 52 102 56 62 
  5 mM butyrate - 260 245 230 181 213 229 
  + 94 91 76 118 46 58 
 
 
Table B-3 Fluorescence intensities and number of analyzed cells (n) per treatment group in 
butyrate dose response study 
FA treatment Fluorescence Intensity Standard Error Cell analyzed (n) 
Butyrate (mM) 0 1 5 10 0 1 5 10 0 1 5 10 
DHA 1690 1972 2071 2113 30.1 29.2 32.7 39.7 306 325 260 176
LA 1669 1887 1749 1802 27.8 27.2 24.4 22.9 360 375 466 531
No FA 1697 1842 1843 1868 21.6 26.0 24.6 28.6 594 409 459 340
 
 
Table B-4 Percentage change in DPPP-oxide intensity following 5 mM butyrate co-incubation 
FA Treatment DHA LA No FA 
Butyrate incubation    
12 h *26.2% 11.1% *21.9% 
24 h *28.7% 9.3% 16.3% 
        
* Indicates a significant change in lipid oxidation following butyrate incubation within a FA group. 
 
 
Table B-5 Differences and statistical significance in the induction of lipid oxidation following 
butyrate co-treatment among different fatty acid treatment groups 
Treatment groups: 
A = without butyrate and Vitamin E   
B = with 5 mM butyrate (no Vitamin E)  
C = with 5mM butyrate and 10 µM Vitamin E 
 
To explain notation:  DHA vs. LA:  A – B 12 h means comparing the difference, A – B, for DHA vs. LA for 
the 12 h data. 
Standard 
Label                       Estimate Error DF t Value Pr > |t| 
 
DHA v. LA: A - B 12h  -76.2967  73.3530    33       -1.04  0.3058 
DHA v. no FA: A - B 12h  -29.6799  72.8201    31.7       -0.41       0.6863 
LA v. no FA: A - B 12h     46.6168 72.4843  31   0.64       0.5249 
 
   
DHA v. no FA: A - B 24h  -85.7469 72.7508  31.9      -1.18  0.2472 
LA v. no FA: A - B 24h    32.9323  73.0122    33.4         0.45     0.6549 
 
DHA v. LA: A - C 12h   -46.0405  129.75   220   -0.35  0.7231 
DHA v. no FA: A - C 12h   35.4460  129.66  219   0.27 0.7848 
LA v. no FA: A - C 12h    81.4865 129.49  219   0.63  0.5298 
 
DHA v. LA: A - C 24h   -73.5267  129.82  221  -0.57 0.5717 
DHA v. no FA: A - C 24h -11.2017 126.50 199  -0.09  0.9295 
LA v. no FA: A - C 24h    62.3250  126.52 202   0.49  0.6228 
 
DHA v. LA: B - C 12h    30.2562  129.87  221   0.23 0.8160 
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DHA v. no FA: B - C 12h   65.1259  129.66  219   0.50 0.6160 
LA v. no FA: B - C 12h    34.8697  129.64  217   0.27  0.7882 
 
DHA v. LA: B - C 24h    45.1525   129.89  222   0.35 0.7285 
DHA v. no FA: B - C 24h     74.5452 126.48 197   0.59 0.5563 
LA v. no FA: B - C 24h  29.3927 126.61 201  0.23 0.8167 
 
 
Table B-6 Analysis of ROS Data – Pooled Dates (8/11 & 9/1/04) 
 
Compare Time, FA & Butyrate 
This analysis was for both dates pooled together.  The analysis was completed using a mixed model in SAS to account 
for the extra variance from subsampling from well. Factors of comparison are FA, time, and butyrate. Date was included 
as a factor to represent the two separate dates. 
 
Type 3 Tests of Fixed Effects 
 
                                          Num     Den 
                     Effect                DF      DF    F Value    Pr > F 
 
                     Date                   1    53.4      20.56    <.0001 * 
                     FA                     2    53.3       1.73    0.1862 
                     butyrate               1    53.3       5.77    0.0198 * 
                     time                   2    53.3      27.46    <.0001 * 
                     FA*butyrate            2    53.3       0.31    0.7322 
                     FA*time                4    53.3       0.81    0.5222 
                     time*butyrate          2    53.3       0.21    0.8084 
                     FA*time*butyrate       4    53.3       0.14    0.9674 
 
Date, butyrate, and time are significant. 
 
The following are the least squares means & standard errors. 
 
                                      Least Squares Means 
 
                                                          Standard 
  Effect             FA      time   butyrate   Estimate      Error     DF   t Value   Pr > |t| 
 
  FA                 DHA                         480.62    20.4197   53.2     23.54     <.0001 
  FA                 LA                          437.40    20.4477   53.5     21.39     <.0001 
  FA                 No-FA                       486.84    20.4460   53.5     23.81     <.0001 
  butyrate                          0mM          496.62    16.6727   53.2     29.79     <.0001 
  butyrate                          5mM          439.95    16.7030   53.6     26.34     <.0001 
  time                       12h                 559.22    20.4351   53.3     27.37     <.0001 
  time                       24h                 495.26    20.4694   53.7     24.20     <.0001 
  time                       6h                  350.37    20.4088   53.1     17.17     <.0001 
  FA*butyrate        DHA            0mM          510.91    28.8745   53.2     17.69     <.0001 
  FA*butyrate        DHA            5mM          450.33    28.8797   53.2     15.59     <.0001 
  FA*butyrate        LA             0mM          453.44    28.8618   53.1     15.71     <.0001 
  FA*butyrate        LA             5mM          421.36    28.9710   53.8     14.54     <.0001 
  FA*butyrate        No-FA          0mM          525.52    28.8933   53.3     18.19     <.0001 
  FA*butyrate        No-FA          5mM          448.16    28.9353   53.6     15.49     <.0001 
  FA*time            DHA     12h                 581.32    35.3811   53.2     16.43     <.0001 
  FA*time            DHA     24h                 482.34    35.3936   53.3     13.63     <.0001 
  FA*time            DHA     6h                  378.19    35.3257   52.9     10.71     <.0001 
  FA*time            LA      12h                 522.58    35.4324   53.5     14.75     <.0001 
  FA*time            LA      24h                 503.03    35.5000   53.9     14.17     <.0001 
  FA*time            LA      6h                  286.60    35.3121   52.8      8.12     <.0001 
  FA*time            No-FA   12h                 573.78    35.3664   53.2     16.22     <.0001 
  FA*time            No-FA   24h                 500.40    35.4646   53.8     14.11     <.0001 
  FA*time            No-FA   6h                  386.33    35.4060   53.4     10.91     <.0001 
  time*butyrate              12h    0mM          585.14    28.8915   53.3     20.25     <.0001 
  time*butyrate              12h    5mM          533.31    28.9060   53.4     18.45     <.0001 
  time*butyrate              24h    0mM          534.02    28.8921   53.3     18.48     <.0001 
  time*butyrate              24h    5mM          456.50    29.0025   54.1     15.74     <.0001 
  time*butyrate              6h     0mM          370.71    28.8460   52.9     12.85     <.0001 
  time*butyrate              6h     5mM          330.04    28.8774   53.2     11.43     <.0001 
  FA*time*butyrate   DHA     12h    0mM          619.87    50.0748   53.4     12.38     <.0001 
  FA*time*butyrate   DHA     12h    5mM          542.77    49.9970   53.1     10.86     <.0001 
  FA*time*butyrate   DHA     24h    0mM          521.56    50.0267   53.2     10.43     <.0001 
  FA*time*butyrate   DHA     24h    5mM          443.12    50.0807   53.4      8.85     <.0001 
  FA*time*butyrate   DHA     6h     0mM          391.29    49.9324   52.8      7.84     <.0001 
  FA*time*butyrate   DHA     6h     5mM          365.09    49.9830     53      7.30     <.0001 
  FA*time*butyrate   LA      12h    0mM          520.52    50.0324   53.2     10.40     <.0001 
  FA*time*butyrate   LA      12h    5mM          524.64    50.1842   53.9     10.45     <.0001 
  FA*time*butyrate   LA      24h    0mM          531.23    50.0631   53.3     10.61     <.0001 
  FA*time*butyrate   LA      24h    5mM          474.83    50.3441   54.5      9.43     <.0001 
  FA*time*butyrate   LA      6h     0mM          308.57    49.8718   52.6      6.19     <.0001 
  FA*time*butyrate   LA      6h     5mM          264.63    50.0050   53.1      5.29     <.0001 
  FA*time*butyrate   No-FA   12h    0mM          615.02    50.0145   53.2     12.30     <.0001 
  FA*time*butyrate   No-FA   12h    5mM          532.53    50.0160   53.2     10.65     <.0001 
  FA*time*butyrate   No-FA   24h    0mM          549.26    50.0359   53.3     10.98     <.0001 
  FA*time*butyrate   No-FA   24h    5mM          451.55    50.2722   54.2      8.98     <.0001 
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  FA*time*butyrate   No-FA   6h     0mM          412.28    50.0814   53.4      8.23     <.0001 
  FA*time*butyrate   No-FA   6h     5mM          360.39    50.0609   53.4      7.20     <.0001 
 
 
Now for pairwise comparisons.  Estimates of differences, standard errors are 
given first, then p-values.  I will highlight all <0.05 and for interaction 
terms, ones that have at least one factor in common: 
  
                                      The Mixed Procedure  
Differences of Least Squares Means 
 
                                                                              Standard 
    Effect            FA     time  butyrate  FA     time  butyrate  Estimate     Error    DF 
 
    FA                DHA                    LA                      43.2168   28.8960  53.3 
    FA                DHA                    No-FA                   -6.2198   28.8950  53.3 
    FA                LA                     No-FA                  -49.4366   28.9146  53.4 
    butyrate                       0mM                    5mM        56.6707   23.5983  53.3 
    time                     12h                    24h              63.9670   28.9222  53.5 
    time                     12h                    6h                208.85   28.8795  53.2 
    time                     24h                    6h                144.88   28.9038  53.4 
    FA*butyrate       DHA          0mM       DHA          5mM        60.5779   40.8374  53.2 
    FA*butyrate       DHA          0mM       LA           0mM        57.4690   40.8247  53.1 
    FA*butyrate       DHA          0mM       LA           5mM        89.5426   40.9018  53.5 
    FA*butyrate       DHA          0mM       No-FA        0mM       -14.6111   40.8471  53.2 
    FA*butyrate       DHA          0mM       No-FA        5mM        62.7495   40.8767  53.4 
    FA*butyrate       DHA          5mM       LA           0mM        -3.1089   40.8283  53.1 
    FA*butyrate       DHA          5mM       LA           5mM        28.9647   40.9054  53.5 
    FA*butyrate       DHA          5mM       No-FA        0mM       -75.1890   40.8507  53.2 
    FA*butyrate       DHA          5mM       No-FA        5mM         2.1716   40.8803  53.4 
    FA*butyrate       LA           0mM       LA           5mM        32.0736   40.8927  53.4 
    FA*butyrate       LA           0mM       No-FA        0mM       -72.0801   40.8380  53.2 
    FA*butyrate       LA           0mM       No-FA        5mM         5.2805   40.8676  53.3 
    FA*butyrate       LA           5mM       No-FA        0mM        -104.15   40.9151  53.6 
    FA*butyrate       LA           5mM       No-FA        5mM       -26.7932   40.9446  53.7 
    FA*butyrate       No-FA        0mM       No-FA        5mM        77.3606   40.8900  53.4 
    FA*time           DHA    12h             DHA    24h              98.9758   50.0444  53.3 
    FA*time           DHA    12h             DHA    6h                203.13   49.9964  53.1 
    FA*time           DHA    12h             LA     12h              58.7414   50.0715  53.4 
    FA*time           DHA    12h             LA     24h              78.2937   50.1193  53.6 
    FA*time           DHA    12h             LA     6h                294.72   49.9868    53 
    FA*time           DHA    12h             No-FA  12h               7.5444   50.0252  53.2 
    FA*time           DHA    12h             No-FA  24h              80.9173   50.0946  53.5 
    FA*time           DHA    12h             No-FA  6h                194.99   50.0530  53.3 
    FA*time           DHA    24h             DHA    6h                104.15   50.0054  53.1 
    FA*time           DHA    24h             LA     12h             -40.2344   50.0806  53.4 
    FA*time           DHA    24h             LA     24h             -20.6822   50.1283  53.6 
    FA*time           DHA    24h             LA     6h                195.75   49.9958  53.1 
    FA*time           DHA    24h             No-FA  12h             -91.4314   50.0342  53.2 
    FA*time           DHA    24h             No-FA  24h             -18.0585   50.1036  53.5 
    FA*time           DHA    24h             No-FA  6h               96.0096   50.0620  53.4 
    FA*time           DHA    6h              LA     12h              -144.39   50.0326  53.2 
    FA*time           DHA    6h              LA     24h              -124.84   50.0804  53.4 
    FA*time           DHA    6h              LA     6h               91.5913   49.9477  52.9 
    FA*time           DHA    6h              No-FA  12h              -195.59   49.9862    53 
    FA*time           DHA    6h              No-FA  24h              -122.21   50.0557  53.3 
    FA*time           DHA    6h              No-FA  6h               -8.1452   50.0140  53.2 
    FA*time           LA     12h             LA     24h              19.5523   50.1554  53.7 
    FA*time           LA     12h             LA     6h                235.98   50.0230  53.2 
    FA*time           LA     12h             No-FA  12h             -51.1970   50.0614  53.4 
    FA*time           LA     12h             No-FA  24h              22.1759   50.1308  53.6 
    FA*time           LA     12h             No-FA  6h                136.24   50.0892  53.5 
    FA*time           LA     24h             LA     6h                216.43   50.0708  53.4 
    FA*time           LA     24h             No-FA  12h             -70.7492   50.1092  53.5 
    FA*time           LA     24h             No-FA  24h               2.6237   50.1785  53.8 
    FA*time           LA     24h             No-FA  6h                116.69   50.1369  53.7 
    FA*time           LA     6h              No-FA  12h              -287.18   49.9766    53 
    FA*time           LA     6h              No-FA  24h              -213.80   50.0461  53.3 
    FA*time           LA     6h              No-FA  6h              -99.7365   50.0045  53.1 
    FA*time           No-FA  12h             No-FA  24h              73.3729   50.0844  53.5 
    FA*time           No-FA  12h             No-FA  6h                187.44   50.0428  53.3 
    FA*time           No-FA  24h             No-FA  6h                114.07   50.1122  53.6 
    time*butyrate            12h   0mM              12h   5mM        51.8229   40.8678  53.3 
    time*butyrate            12h   0mM              24h   0mM        51.1205   40.8582  53.3 
    time*butyrate            12h   0mM              24h   5mM         128.64   40.9359  53.7 
    time*butyrate            12h   0mM              6h    0mM         214.43   40.8255  53.1 
    time*butyrate            12h   0mM              6h    5mM         255.10   40.8477  53.2 
    time*butyrate            12h   5mM              24h   0mM        -0.7024   40.8685  53.3 
    time*butyrate            12h   5mM              24h   5mM        76.8135   40.9462  53.7 
    time*butyrate            12h   5mM              6h    0mM         162.60   40.8358  53.2 
    time*butyrate            12h   5mM              6h    5mM         203.28   40.8580  53.3 
    time*butyrate            24h   0mM              24h   5mM        77.5160   40.9366  53.7 
    time*butyrate            24h   0mM              6h    0mM         163.31   40.8261  53.1 
    time*butyrate            24h   0mM              6h    5mM         203.98   40.8483  53.2 
    time*butyrate            24h   5mM              6h    0mM        85.7891   40.9040  53.5 
    time*butyrate             24h  5mM               6h     5mM          126.46    40.9261   53.6                                    
    time*butyrate            6h    0mM              6h    5mM        40.6733   40.8156    53 
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The Mixed Procedure 
 
                               Differences of Least Squares Means 
                       Standard 
Effect            FA     time  butyrate  FA     time  butyrate  Estimate     Error    DF 
 
    FA*time*butyrate  DHA    12h   0mM       DHA    12h   5mM        77.0993   70.7607  53.2 
    FA*time*butyrate  DHA    12h   0mM       DHA    24h   0mM        98.3053   70.7819  53.3 
    FA*time*butyrate  DHA    12h   0mM       DHA    24h   5mM         176.75   70.8199  53.4 
    FA*time*butyrate  DHA    12h   0mM       DHA    6h    0mM         228.58   70.7152  53.1 
    FA*time*butyrate  DHA    12h   0mM       DHA    6h    5mM         254.78   70.7508  53.2 
    FA*time*butyrate  DHA    12h   0mM       LA     12h   0mM        99.3512   70.7857  53.3 
    FA*time*butyrate  DHA    12h   0mM       LA     12h   5mM        95.2309   70.8929  53.6 
    FA*time*butyrate  DHA    12h   0mM       LA     24h   0mM        88.6442   70.8073  53.4 
    FA*time*butyrate  DHA    12h   0mM       LA     24h   5mM         145.04   71.0061    54 
    FA*time*butyrate  DHA    12h   0mM       LA     6h    0mM         311.30   70.6725    53 
    FA*time*butyrate  DHA    12h   0mM       LA     6h    5mM         355.24   70.7665  53.3 
    FA*time*butyrate  DHA    12h   0mM       No-FA  12h   0mM         4.8493   70.7732  53.3 
    FA*time*butyrate  DHA    12h   0mM       No-FA  12h   5mM        87.3389   70.7744  53.3 
    FA*time*butyrate  DHA    12h   0mM       No-FA  24h   0mM        70.6124   70.7886  53.3 
    FA*time*butyrate  DHA    12h   0mM       No-FA  24h   5mM         168.32   70.9553  53.8 
    FA*time*butyrate  DHA    12h   0mM       No-FA  6h    0mM         207.59   70.8204  53.4 
    FA*time*butyrate  DHA    12h   0mM       No-FA  6h    5mM         259.48   70.8059  53.4 
    FA*time*butyrate  DHA    12h   5mM       DHA    24h   0mM        21.2060   70.7270  53.1 
FA*time*butyrate  DHA    12h   5mM       DHA    24h   5mM        99.6464   70.7649  53.3 
    FA*time*butyrate  DHA    12h   5mM       DHA    6h    0mM         151.48   70.6602  52.9 
    FA*time*butyrate  DHA    12h   5mM       DHA    6h    5mM         177.68   70.6959    53 
    FA*time*butyrate  DHA    12h   5mM       LA     12h   0mM        22.2519   70.7307  53.1 
    FA*time*butyrate  DHA    12h   5mM       LA     12h   5mM        18.1316   70.8380  53.5 
    FA*time*butyrate  DHA    12h   5mM       LA     24h   0mM        11.5449   70.7524  53.2 
    FA*time*butyrate  DHA    12h   5mM       LA     24h   5mM        67.9432   70.9514  53.8 
    FA*time*butyrate  DHA    12h   5mM       LA     6h    0mM         234.20   70.6174  52.8 
    FA*time*butyrate  DHA    12h   5mM       LA     6h    5mM         278.14   70.7115  53.1 
    FA*time*butyrate  DHA    12h   5mM       No-FA  12h   0mM       -72.2500   70.7182  53.1 
    FA*time*butyrate  DHA    12h   5mM       No-FA  12h   5mM        10.2396   70.7194  53.1 
    FA*time*butyrate  DHA    12h   5mM       No-FA  24h   0mM        -6.4869   70.7336  53.2 
    FA*time*butyrate  DHA    12h   5mM       No-FA  24h   5mM        91.2223   70.9005  53.7 
    FA*time*butyrate  DHA    12h   5mM       No-FA  6h    0mM         130.49   70.7654  53.3 
    FA*time*butyrate  DHA    12h   5mM       No-FA  6h    5mM         182.38   70.7509  53.2 
    FA*time*butyrate  DHA    24h   0mM       DHA    24h   5mM        78.4404   70.7862  53.3 
    FA*time*butyrate  DHA    24h   0mM       DHA    6h    0mM         130.28   70.6814    53 
    FA*time*butyrate  DHA    24h   0mM       DHA    6h    5mM         156.47   70.7171  53.1 
    FA*time*butyrate  DHA    24h   0mM       LA     12h   0mM         1.0459   70.7520  53.2 
    FA*time*butyrate  DHA    24h   0mM       LA     12h   5mM        -3.0744   70.8593  53.5 
    FA*time*butyrate  DHA    24h   0mM       LA     24h   0mM        -9.6611   70.7737  53.3 
    FA*time*butyrate  DHA    24h   0mM       LA     24h   5mM        46.7372   70.9726  53.9 
    FA*time*butyrate  DHA    24h   0mM       LA     6h    0mM         212.99   70.6387  52.9 
    FA*time*butyrate  DHA    24h   0mM       LA     6h    5mM         256.94   70.7327  53.2 
    FA*time*butyrate  DHA    24h   0mM       No-FA  12h   0mM       -93.4560   70.7394  53.2 
    FA*time*butyrate  DHA    24h   0mM       No-FA  12h   5mM       -10.9664   70.7406  53.2 
    FA*time*butyrate  DHA    24h   0mM       No-FA  24h   0mM       -27.6929   70.7547  53.2 
    FA*time*butyrate  DHA    24h   0mM       No-FA  24h   5mM        70.0163   70.9217  53.7 
    FA*time*butyrate  DHA    24h   0mM       No-FA  6h    0mM         109.29   70.7867  53.3 
    FA*time*butyrate  DHA    24h   0mM       No-FA  6h    5mM         161.17   70.7722  53.3 
    FA*time*butyrate  DHA    24h   5mM       DHA    6h    0mM        51.8376   70.7195  53.1 
    FA*time*butyrate  DHA    24h   5mM       DHA    6h    5mM        78.0316   70.7551  53.2 
    FA*time*butyrate  DHA    24h   5mM       LA     12h   0mM       -77.3945   70.7899  53.3 
    FA*time*butyrate  DHA    24h   5mM       LA     12h   5mM       -81.5148   70.8972  53.6 
    FA*time*butyrate  DHA    24h   5mM       LA     24h   0mM       -88.1015   70.8116  53.4 
    FA*time*butyrate  DHA    24h   5mM       LA     24h   5mM       -31.7033   71.0104    54 
    FA*time*butyrate  DHA    24h   5mM       LA     6h    0mM         134.55   70.6767    53 
    FA*time*butyrate  DHA    24h   5mM       LA     6h    5mM         178.50   70.7707  53.3 
    FA*time*butyrate  DHA    24h   5mM       No-FA  12h   0mM        -171.90   70.7774  53.3 
    FA*time*butyrate  DHA    24h   5mM       No-FA  12h   5mM       -89.4068   70.7786  53.3 
    FA*time*butyrate  DHA    24h   5mM       No-FA  24h   0mM        -106.13   70.7928  53.3 
    FA*time*butyrate  DHA    24h   5mM       No-FA  24h   5mM        -8.4241   70.9595  53.8 
    FA*time*butyrate  DHA    24h   5mM       No-FA  6h    0mM        30.8479   70.8246  53.4 
    FA*time*butyrate  DHA    24h   5mM       No-FA  6h    5mM        82.7308   70.8101  53.4 
    FA*time*butyrate  DHA    6h    0mM       DHA    6h    5mM        26.1940   70.6504  52.9 
    FA*time*butyrate  DHA    6h    0mM       LA     12h   0mM        -129.23   70.6853    53 
    FA*time*butyrate  DHA    6h    0mM       LA     12h   5mM        -133.35   70.7927  53.3 
    FA*time*butyrate  DHA    6h    0mM       LA     24h   0mM        -139.94   70.7069  53.1 
    FA*time*butyrate  DHA    6h    0mM       LA     24h   5mM       -83.5409   70.9061  53.7 
    FA*time*butyrate  DHA    6h    0mM       LA     6h    0mM        82.7169   70.5718  52.7 
    FA*time*butyrate  DHA    6h    0mM       LA     6h    5mM         126.66   70.6660    53 
    FA*time*butyrate  DHA    6h    0mM       No-FA  12h   0mM        -223.73   70.6727    53 
    FA*time*butyrate  DHA    6h    0mM       No-FA  12h   5mM        -141.24   70.6739    53 
    FA*time*butyrate  DHA    6h    0mM       No-FA  24h   0mM        -157.97   70.6880    53 
    FA*time*butyrate  DHA    6h    0mM       No-FA  24h   5mM       -60.2618   70.8551  53.5 
    FA*time*butyrate  DHA    6h    0mM       No-FA  6h    0mM       -20.9897   70.7200  53.1 
    FA*time*butyrate  DHA    6h    0mM       No-FA  6h    5mM        30.8932   70.7054  53.1 
    FA*time*butyrate  DHA    6h    5mM       LA     12h   0mM        -155.43   70.7209  53.1 
    FA*time*butyrate  DHA    6h    5mM       LA     12h   5mM        -159.55   70.8282  53.4 
    FA*time*butyrate  DHA    6h    5mM       LA     24h   0mM        -166.13   70.7425  53.2 
    FA*time*butyrate  DHA    6h    5mM       LA     24h   5mM        -109.73   70.9416  53.8 
    FA*time*butyrate  DHA    6h    5mM       LA     6h    0mM        56.5228   70.6075  52.8 
    FA*time*butyrate  DHA    6h    5mM       LA     6h    5mM         100.47   70.7016  53.1 
    FA*time*butyrate  DHA    6h    5mM       No-FA  12h   0mM        -249.93   70.7083  53.1 
    FA*time*butyrate  DHA    6h    5mM       No-FA  12h   5mM        -167.44   70.7095  53.1 
    FA*time*butyrate  DHA    6h    5mM       No-FA  24h   0mM        -184.16   70.7237  53.1 
    FA*time*butyrate  DHA    6h    5mM       No-FA  24h   5mM       -86.4558   70.8906  53.6 
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    FA*time*butyrate  DHA    6h    5mM       No-FA  6h    0mM       -47.1837   70.7556  53.2 
    FA*time*butyrate  DHA    6h    5mM       No-FA  6h    5mM         4.6992   70.7411  53.2 
    FA*time*butyrate  LA     12h   0mM       LA     12h   5mM        -4.1203   70.8630  53.5 
    FA*time*butyrate  LA     12h   0mM       LA     24h   0mM       -10.7070   70.7774  53.3 
    FA*time*butyrate  LA     12h   0mM       LA     24h   5mM        45.6913   70.9763  53.9 
    FA*time*butyrate  LA     12h   0mM       LA     6h    0mM         211.95   70.6425  52.9 
    FA*time*butyrate  LA     12h   0mM       LA     6h    5mM         255.89   70.7365  53.2 
    FA*time*butyrate  LA     12h   0mM       No-FA  12h   0mM       -94.5019   70.7432  53.2 
    FA*time*butyrate  LA     12h   0mM       No-FA  12h   5mM       -12.0123   70.7444  53.2 
    FA*time*butyrate  LA     12h   0mM       No-FA  24h   0mM       -28.7388   70.7586  53.2 
    FA*time*butyrate  LA     12h   0mM       No-FA  24h   5mM        68.9704   70.9254  53.7 
    FA*time*butyrate  LA     12h   0mM       No-FA  6h    0mM         108.24   70.7904  53.3 
    FA*time*butyrate  LA     12h   0mM       No-FA  6h    5mM         160.13   70.7759  53.3 
    FA*time*butyrate  LA     12h   5mM       LA     24h   0mM        -6.5867   70.8846  53.6 
    FA*time*butyrate  LA     12h   5mM       LA     24h   5mM        49.8115   71.0832  54.2 
    FA*time*butyrate  LA     12h   5mM       LA     6h    0mM         216.07   70.7499  53.2 
    FA*time*butyrate  LA     12h   5mM       LA     6h    5mM         260.01   70.8438  53.5 
    FA*time*butyrate  LA     12h   5mM       No-FA  12h   0mM       -90.3816   70.8505  53.5 
    FA*time*butyrate  LA     12h   5mM       No-FA  12h   5mM        -7.8920   70.8518  53.5 
    FA*time*butyrate  LA     12h   5mM       No-FA  24h   0mM       -24.6185   70.8659  53.6 
    FA*time*butyrate  LA     12h   5mM       No-FA  24h   5mM        73.0906   71.0324    54 
    FA*time*butyrate  LA     12h   5mM       No-FA  6h    0mM         112.36   70.8976  53.6 
    FA*time*butyrate  LA     12h   5mM       No-FA  6h    5mM         164.25   70.8832  53.6 
    FA*time*butyrate  LA     24h   0mM       LA     24h   5mM        56.3983   70.9978  53.9 
    FA*time*butyrate  LA     24h   0mM       LA     6h    0mM         222.66   70.6642    53 
    FA*time*butyrate  LA     24h   0mM       LA     6h    5mM         266.60   70.7582  53.2 
    FA*time*butyrate  LA     24h   0mM       No-FA  12h   0mM       -83.7949   70.7649  53.2 
    FA*time*butyrate  LA     24h   0mM       No-FA  12h   5mM        -1.3053   70.7661  53.3 
    FA*time*butyrate  LA     24h   0mM       No-FA  24h   0mM       -18.0318   70.7803  53.3 
    FA*time*butyrate  LA     24h   0mM       No-FA  24h   5mM        79.6774   70.9470  53.8 
    FA*time*butyrate  LA     24h   0mM       No-FA  6h    0mM         118.95   70.8121  53.4 
    FA*time*butyrate  LA     24h   0mM       No-FA  6h    5mM         170.83   70.7975  53.3 
    FA*time*butyrate  LA     24h   5mM       LA     6h    0mM         166.26   70.8634  53.5 
    FA*time*butyrate  LA     24h   5mM       LA     6h    5mM         210.20   70.9572  53.8 
    FA*time*butyrate  LA     24h   5mM       No-FA  12h   0mM        -140.19   70.9638  53.8 
    FA*time*butyrate  LA     24h   5mM       No-FA  12h   5mM       -57.7036   70.9651  53.8 
    FA*time*butyrate  LA     24h   5mM       No-FA  24h   0mM       -74.4301   70.9792  53.9 
    FA*time*butyrate  LA     24h   5mM       No-FA  24h   5mM        23.2791   71.1454  54.4 
    FA*time*butyrate  LA     24h   5mM       No-FA  6h    0mM        62.5512   71.0109    54 
    FA*time*butyrate  LA     24h   5mM       No-FA  6h    5mM         114.43   70.9964  53.9 
    FA*time*butyrate  LA     6h    0mM       LA     6h    5mM        43.9429   70.6232  52.8 
    FA*time*butyrate  LA     6h    0mM       No-FA  12h   0mM        -306.45   70.6299  52.9 
    FA*time*butyrate  LA     6h    0mM       No-FA  12h   5mM        -223.96   70.6311  52.9 
    FA*time*butyrate  LA     6h    0mM       No-FA  24h   0mM        -240.69   70.6453  52.9 
    FA*time*butyrate  LA     6h    0mM       No-FA  24h   5mM        -142.98   70.8124  53.4 
    FA*time*butyrate  LA     6h    0mM       No-FA  6h    0mM        -103.71   70.6772    53 
    FA*time*butyrate  LA     6h    0mM       No-FA  6h    5mM       -51.8236   70.6627    53 
    FA*time*butyrate  LA     6h    5mM       No-FA  12h   0mM        -350.39   70.7240  53.1 
    FA*time*butyrate  LA     6h    5mM       No-FA  12h   5mM        -267.90   70.7252  53.1 
    FA*time*butyrate  LA     6h    5mM       No-FA  24h   0mM        -284.63   70.7393  53.2 
    FA*time*butyrate  LA     6h    5mM       No-FA  24h   5mM        -186.92   70.9063  53.7 
    FA*time*butyrate  LA     6h    5mM       No-FA  6h    0mM        -147.65   70.7712  53.3 
    FA*time*butyrate  LA     6h    5mM       No-FA  6h    5mM       -95.7665   70.7567  53.2 
    FA*time*butyrate  No-FA  12h   0mM       No-FA  12h   5mM        82.4896   70.7319  53.2 
    FA*time*butyrate  No-FA  12h   0mM       No-FA  24h   0mM        65.7631   70.7460  53.2 
    FA*time*butyrate  No-FA  12h   0mM       No-FA  24h   5mM         163.47   70.9129  53.7 
    FA*time*butyrate  No-FA  12h   0mM       No-FA  6h    0mM         202.74   70.7779  53.3 
    FA*time*butyrate  No-FA  12h   0mM       No-FA  6h    5mM         254.63   70.7634  53.3 
    FA*time*butyrate  No-FA  12h   5mM       No-FA  24h   0mM       -16.7265   70.7472  53.2 
    FA*time*butyrate  No-FA  12h   5mM       No-FA  24h   5mM        80.9827   70.9142  53.7 
    FA*time*butyrate  No-FA  12h   5mM       No-FA  6h    0mM         120.25   70.7791  53.3 
    FA*time*butyrate  No-FA  12h   5mM       No-FA  6h    5mM         172.14   70.7646  53.3 
    FA*time*butyrate  No-FA  24h   0mM       No-FA  24h   5mM        97.7092   70.9283  53.7 
    FA*time*butyrate  No-FA  24h   0mM       No-FA  6h    0mM         136.98   70.7933  53.3 
    FA*time*butyrate  No-FA  24h   0mM       No-FA  6h    5mM         188.86   70.7788  53.3 
    FA*time*butyrate  No-FA  24h   5mM       No-FA  6h    0mM        39.2721   70.9600  53.8 
    FA*time*butyrate  No-FA  24h   5mM       No-FA  6h    5mM        91.1550   70.9455  53.8 
    FA*time*butyrate  No-FA  6h    0mM       No-FA  6h    5mM        51.8829   70.8106  53.4 
 
P-VALUES:                             
Differences of Least Squares Means 
 
       Effect            FA     time  butyrate  FA     time  butyrate  t Value   Pr > |t| 
 
Effect of FA: 
 
       FA                DHA                    LA                        1.50     0.1407 
       FA                DHA                    No-FA                    -0.22     0.8304 
       FA                LA                     No-FA                    -1.71     0.0931 
 
None significant at alpha=0.05 
 
Effect of butyrate: 
 
       Butyrate                       0mM                    5mM          2.40     0.0198 * 
 
Significant. 
 
Effect of time: 
 
       time                     12h                    24h                2.21     0.0313 * 
       time                     12h                    6h                 7.23     <.0001 * 
   
   
86
       time                     24h                    6h                 5.01     <.0001 * 
 
All times are significantly different. 
 
Effect of Fa*butyrate: 
 
       FA*butyrate       DHA          0mM       DHA          5mM          1.48     0.1439 
       FA*butyrate       DHA          0mM       LA           0mM          1.41     0.1650 
       FA*butyrate       DHA          0mM       LA           5mM          2.19     0.0330 
       FA*butyrate       DHA          0mM       No-FA        0mM         -0.36     0.7220 
       FA*butyrate       DHA          0mM       No-FA        5mM          1.54     0.1307 
       FA*butyrate       DHA          5mM       LA           0mM         -0.08     0.9396 
       FA*butyrate       DHA          5mM       LA           5mM          0.71     0.4820 
       FA*butyrate       DHA          5mM       No-FA        0mM         -1.84     0.0713 
       FA*butyrate       DHA          5mM       No-FA        5mM          0.05     0.9578 
       FA*butyrate       LA           0mM       LA           5mM          0.78     0.4363 
       FA*butyrate       LA           0mM       No-FA        0mM         -1.77     0.0833 * 
       FA*butyrate       LA           0mM       No-FA        5mM          0.13     0.8977 
       FA*butyrate       LA           5mM       No-FA        0mM         -2.55     0.0138 
       FA*butyrate       LA           5mM       No-FA        5mM         -0.65     0.5157 
       FA*butyrate       No-FA        0mM       No-FA        5mM          1.89     0.0639 * 
 
 
                                     Differences of Least Squares Means 
 
       Effect            FA     time  butyrate  FA     time  butyrate  t Value   Pr > |t| 
 
Effect of FA*time: 
 
       FA*time           DHA    12h             DHA    24h                1.98     0.0531 * 
       FA*time           DHA    12h             DHA    6h                 4.06     0.0002 * 
       FA*time           DHA    12h             LA     12h                1.17     0.2459 
       FA*time           DHA    12h             LA     24h                1.56     0.1241 
       FA*time           DHA    12h             LA     6h                 5.90     <.0001 
       FA*time           DHA    12h             No-FA  12h                0.15     0.8807 
       FA*time           DHA    12h             No-FA  24h                1.62     0.1121 
       FA*time           DHA    12h             No-FA  6h                 3.90     0.0003 
       FA*time           DHA    24h             DHA    6h                 2.08     0.0421 * 
       FA*time           DHA    24h             LA     12h               -0.80     0.4253 
       FA*time           DHA    24h             LA     24h               -0.41     0.6816 
       FA*time           DHA    24h             LA     6h                 3.92     0.0003 
       FA*time           DHA    24h             No-FA  12h               -1.83     0.0732 
       FA*time           DHA    24h             No-FA  24h               -0.36     0.7199 
       FA*time           DHA    24h             No-FA  6h                 1.92     0.0605 
       FA*time           DHA    6h              LA     12h               -2.89     0.0056 
       FA*time           DHA    6h              LA     24h               -2.49     0.0158 
       FA*time           DHA    6h              LA     6h                 1.83     0.0723 * 
       FA*time           DHA    6h              No-FA  12h               -3.91     0.0003 
       FA*time           DHA    6h              No-FA  24h               -2.44     0.0180 
       FA*time           DHA    6h              No-FA  6h                -0.16     0.8712 
       FA*time           LA     12h             LA     24h                0.39     0.6982 
       FA*time           LA     12h             LA     6h                 4.72     <.0001 * 
       FA*time           LA     12h             No-FA  12h               -1.02     0.3111 
       FA*time           LA     12h             No-FA  24h                0.44     0.6600 
       FA*time           LA     12h             No-FA  6h                 2.72     0.0088 
       FA*time           LA     24h             LA     6h                 4.32     <.0001 * 
       FA*time           LA     24h             No-FA  12h               -1.41     0.1638 
       FA*time           LA     24h             No-FA  24h                0.05     0.9585 
       FA*time           LA     24h             No-FA  6h                 2.33     0.0237 
       FA*time           LA     6h              No-FA  12h               -5.75     <.0001 
       FA*time           LA     6h              No-FA  24h               -4.27     <.0001 
       FA*time           LA     6h              No-FA  6h                -1.99     0.0512 * 
       FA*time           No-FA  12h             No-FA  24h                1.46     0.1488 
       FA*time           No-FA  12h             No-FA  6h                 3.75     0.0004 * 
       FA*time           No-FA  24h             No-FA  6h                 2.28     0.0269 * 
 
Effect of time*butyrate: 
 
       time*butyrate            12h   0mM              12h   5mM          1.27     0.2103 
       time*butyrate            12h   0mM              24h   0mM          1.25     0.2163 
       time*butyrate            12h   0mM              24h   5mM          3.14     0.0027 
       time*butyrate            12h   0mM              6h    0mM          5.25     <.0001 * 
       time*butyrate            12h   0mM              6h    5mM          6.25     <.0001 
       time*butyrate            12h   5mM              24h   0mM         -0.02     0.9864 
       time*butyrate            12h   5mM              24h   5mM          1.88     0.0661 * 
       time*butyrate            12h   5mM              6h    0mM          3.98     0.0002 
       time*butyrate            12h   5mM              6h    5mM          4.98     <.0001 * 
       time*butyrate            24h   0mM              24h   5mM          1.89     0.0637 * 
       time*butyrate            24h   0mM              6h    0mM          4.00     0.0002 * 
       time*butyrate            24h   0mM              6h    5mM          4.99     <.0001 
       time*butyrate            24h   5mM              6h    0mM          2.10     0.0407 
       time*butyrate            24h   5mM              6h    5mM          3.09     0.0032 * 
       time*butyrate            6h    0mM              6h    5mM          1.00     0.3235 
 
 
Effect of FA*time*butyrate 
 
       FA*time*butyrate  DHA    12h   0mM       DHA    12h   5mM          1.09     0.2808 
       FA*time*butyrate  DHA    12h   0mM       DHA    24h   0mM          1.39     0.1707 
       FA*time*butyrate  DHA    12h   0mM       DHA    24h   5mM          2.50     0.0157 
       FA*time*butyrate  DHA    12h   0mM       DHA    6h    0mM          3.23     0.0021 * 
                                      Differences of Least Squares Means 
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       Effect            FA     time  butyrate  FA     time  butyrate  t Value   Pr > |t|       
 
FA*time*butyrate  DHA    12h   0mM       DHA    6h    5mM          3.60     0.0007 
       FA*time*butyrate  DHA    12h   0mM       LA     12h   0mM          1.40     0.1663 
       FA*time*butyrate  DHA    12h   0mM       LA     12h   5mM          1.34     0.1848 
       FA*time*butyrate  DHA    12h   0mM       LA     24h   0mM          1.25     0.2161 
       FA*time*butyrate  DHA    12h   0mM       LA     24h   5mM          2.04     0.0460 
       FA*time*butyrate  DHA    12h   0mM       LA     6h    0mM          4.40     <.0001 
       FA*time*butyrate  DHA    12h   0mM       LA     6h    5mM          5.02     <.0001 
       FA*time*butyrate  DHA    12h   0mM       No-FA  12h   0mM          0.07     0.9456 
       FA*time*butyrate  DHA    12h   0mM       No-FA  12h   5mM          1.23     0.2226 
       FA*time*butyrate  DHA    12h   0mM       No-FA  24h   0mM          1.00     0.3230 
       FA*time*butyrate  DHA    12h   0mM       No-FA  24h   5mM          2.37     0.0213 
       FA*time*butyrate  DHA    12h   0mM       No-FA  6h    0mM          2.93     0.0050 
       FA*time*butyrate  DHA    12h   0mM       No-FA  6h    5mM          3.66     0.0006 
       FA*time*butyrate  DHA    12h   5mM       DHA    24h   0mM          0.30     0.7655 
       FA*time*butyrate  DHA    12h   5mM       DHA    24h   5mM          1.41     0.1649 
       FA*time*butyrate  DHA    12h   5mM       DHA    6h    0mM          2.14     0.0367 
       FA*time*butyrate  DHA    12h   5mM       DHA    6h    5mM          2.51     0.0150 * 
       FA*time*butyrate  DHA    12h   5mM       LA     12h   0mM          0.31     0.7543 
       FA*time*butyrate  DHA    12h   5mM       LA     12h   5mM          0.26     0.7990 
       FA*time*butyrate  DHA    12h   5mM       LA     24h   0mM          0.16     0.8710 
       FA*time*butyrate  DHA    12h   5mM       LA     24h   5mM          0.96     0.3425 
       FA*time*butyrate  DHA    12h   5mM       LA     6h    0mM          3.32     0.0017 
       FA*time*butyrate  DHA    12h   5mM       LA     6h    5mM          3.93     0.0002 
       FA*time*butyrate  DHA    12h   5mM       No-FA  12h   0mM         -1.02     0.3116 
       FA*time*butyrate  DHA    12h   5mM       No-FA  12h   5mM          0.14     0.8854 
       FA*time*butyrate  DHA    12h   5mM       No-FA  24h   0mM         -0.09     0.9273 
       FA*time*butyrate  DHA    12h   5mM       No-FA  24h   5mM          1.29     0.2037 
       FA*time*butyrate  DHA    12h   5mM       No-FA  6h    0mM          1.84     0.0707 
       FA*time*butyrate  DHA    12h   5mM       No-FA  6h    5mM          2.58     0.0127 
       FA*time*butyrate  DHA    24h   0mM       DHA    24h   5mM          1.11     0.2728 
       FA*time*butyrate  DHA    24h   0mM       DHA    6h    0mM          1.84     0.0709 * 
       FA*time*butyrate  DHA    24h   0mM       DHA    6h    5mM          2.21     0.0312 
       FA*time*butyrate  DHA    24h   0mM       LA     12h   0mM          0.01     0.9883 
       FA*time*butyrate  DHA    24h   0mM       LA     12h   5mM         -0.04     0.9656 
       FA*time*butyrate  DHA    24h   0mM       LA     24h   0mM         -0.14     0.8919 
       FA*time*butyrate  DHA    24h   0mM       LA     24h   5mM          0.66     0.5130 
       FA*time*butyrate  DHA    24h   0mM       LA     6h    0mM          3.02     0.0039 
       FA*time*butyrate  DHA    24h   0mM       LA     6h    5mM          3.63     0.0006 
       FA*time*butyrate  DHA    24h   0mM       No-FA  12h   0mM         -1.32     0.1921 
       FA*time*butyrate  DHA    24h   0mM       No-FA  12h   5mM         -0.16     0.8774 
       FA*time*butyrate  DHA    24h   0mM       No-FA  24h   0mM         -0.39     0.6971 
       FA*time*butyrate  DHA    24h   0mM       No-FA  24h   5mM          0.99     0.3280 
       FA*time*butyrate  DHA    24h   0mM       No-FA  6h    0mM          1.54     0.1285 
       FA*time*butyrate  DHA    24h   0mM       No-FA  6h    5mM          2.28     0.0268 
       FA*time*butyrate  DHA    24h   5mM       DHA    6h    0mM          0.73     0.4668 
       FA*time*butyrate  DHA    24h   5mM       DHA    6h    5mM          1.10     0.2751 
       FA*time*butyrate  DHA    24h   5mM       LA     12h   0mM         -1.09     0.2792 
       FA*time*butyrate  DHA    24h   5mM       LA     12h   5mM         -1.15     0.2553 
       FA*time*butyrate  DHA    24h   5mM       LA     24h   0mM         -1.24     0.2189 
       FA*time*butyrate  DHA    24h   5mM       LA     24h   5mM         -0.45     0.6571 
       FA*time*butyrate  DHA    24h   5mM       LA     6h    0mM          1.90     0.0624 
       FA*time*butyrate  DHA    24h   5mM       LA     6h    5mM          2.52     0.0147 
       FA*time*butyrate  DHA    24h   5mM       No-FA  12h   0mM         -2.43     0.0186 
       FA*time*butyrate  DHA    24h   5mM       No-FA  12h   5mM         -1.26     0.2120 
       FA*time*butyrate  DHA    24h   5mM       No-FA  24h   0mM         -1.50     0.1397 
       FA*time*butyrate  DHA    24h   5mM       No-FA  24h   5mM         -0.12     0.9059 
       FA*time*butyrate  DHA    24h   5mM       No-FA  6h    0mM          0.44     0.6649 
       FA*time*butyrate  DHA    24h   5mM       No-FA  6h    5mM          1.17     0.2479 
       FA*time*butyrate  DHA    6h    0mM       DHA    6h    5mM          0.37     0.7123 
       FA*time*butyrate  DHA    6h    0mM       LA     12h   0mM         -1.83     0.0731 
       FA*time*butyrate  DHA    6h    0mM       LA     12h   5mM         -1.88     0.0651 
       FA*time*butyrate  DHA    6h    0mM       LA     24h   0mM         -1.98     0.0530 
       FA*time*butyrate  DHA    6h    0mM       LA     24h   5mM         -1.18     0.2439 
       FA*time*butyrate  DHA    6h    0mM       LA     6h    0mM          1.17     0.2464 
       FA*time*butyrate  DHA    6h    0mM       LA     6h    5mM          1.79     0.0788 
       FA*time*butyrate  DHA    6h    0mM       No-FA  12h   0mM         -3.17     0.0026 
       FA*time*butyrate  DHA    6h    0mM       No-FA  12h   5mM         -2.00     0.0508 
       FA*time*butyrate  DHA    6h    0mM       No-FA  24h   0mM         -2.23     0.0297 
       FA*time*butyrate  DHA    6h    0mM       No-FA  24h   5mM         -0.85     0.3988 
       FA*time*butyrate  DHA    6h    0mM       No-FA  6h    0mM         -0.30     0.7678 
       FA*time*butyrate  DHA    6h    0mM       No-FA  6h    5mM          0.44     0.6639 
       FA*time*butyrate  DHA    6h    5mM       LA     12h   0mM         -2.20     0.0323 
       FA*time*butyrate  DHA    6h    5mM       LA     12h   5mM         -2.25     0.0284 
       FA*time*butyrate  DHA    6h    5mM       LA     24h   0mM         -2.35     0.0226 
       FA*time*butyrate  DHA    6h    5mM       LA     24h   5mM         -1.55     0.1278 
       FA*time*butyrate  DHA    6h    5mM       LA     6h    0mM          0.80     0.4270 
       FA*time*butyrate  DHA    6h    5mM       LA     6h    5mM          1.42     0.1612 
       FA*time*butyrate  DHA    6h    5mM       No-FA  12h   0mM         -3.53     0.0009 
       FA*time*butyrate  DHA    6h    5mM       No-FA  12h   5mM         -2.37     0.0216 
       FA*time*butyrate  DHA    6h    5mM       No-FA  24h   0mM         -2.60     0.0119 
       FA*time*butyrate  DHA    6h    5mM       No-FA  24h   5mM         -1.22     0.2280 
       FA*time*butyrate  DHA    6h    5mM       No-FA  6h    0mM         -0.67     0.5077 
       FA*time*butyrate  DHA    6h    5mM       No-FA  6h    5mM          0.07     0.9473 
       FA*time*butyrate  LA     12h   0mM       LA     12h   5mM         -0.06     0.9539 
       FA*time*butyrate  LA     12h   0mM       LA     24h   0mM         -0.15     0.8803 
       FA*time*butyrate  LA     12h   0mM       LA     24h   5mM          0.64     0.5225 
       FA*time*butyrate  LA     12h   0mM       LA     6h    0mM          3.00     0.0041 * 
       FA*time*butyrate  LA     12h   0mM       LA     6h    5mM          3.62     0.0007 
       FA*time*butyrate  LA     12h   0mM       No-FA  12h   0mM         -1.34     0.1873 
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       FA*time*butyrate  LA     12h   0mM       No-FA  12h   5mM         -0.17     0.8658 
       FA*time*butyrate  LA     12h   0mM       No-FA  24h   0mM         -0.41     0.6863 
       FA*time*butyrate  LA     12h   0mM       No-FA  24h   5mM          0.97     0.3352 
       FA*time*butyrate  LA     12h   0mM       No-FA  6h    0mM          1.53     0.1322 
       FA*time*butyrate  LA     12h   0mM       No-FA  6h    5mM          2.26     0.0278 
       FA*time*butyrate  LA     12h   5mM       LA     24h   0mM         -0.09     0.9263 
       FA*time*butyrate  LA     12h   5mM       LA     24h   5mM          0.70     0.4865 
       FA*time*butyrate  LA     12h   5mM       LA     6h    0mM          3.05     0.0035 
       FA*time*butyrate  LA     12h   5mM       LA     6h    5mM          3.67     0.0006 
       FA*time*butyrate  LA     12h   5mM       No-FA  12h   0mM         -1.28     0.2076 
       FA*time*butyrate  LA     12h   5mM       No-FA  12h   5mM         -0.11     0.9117 
       FA*time*butyrate  LA     12h   5mM       No-FA  24h   0mM         -0.35     0.7297 
       FA*time*butyrate  LA     12h   5mM       No-FA  24h   5mM          1.03     0.3081 
       FA*time*butyrate  LA     12h   5mM       No-FA  6h    0mM          1.58     0.1189 
       FA*time*butyrate  LA     12h   5mM       No-FA  6h    5mM          2.32     0.0243 
       FA*time*butyrate  LA     24h   0mM       LA     24h   5mM          0.79     0.4305 
       FA*time*butyrate  LA     24h   0mM       LA     6h    0mM          3.15     0.0027 * 
       FA*time*butyrate  LA     24h   0mM       LA     6h    5mM          3.77     0.0004 
       FA*time*butyrate  LA     24h   0mM       No-FA  12h   0mM         -1.18     0.2416 
       FA*time*butyrate  LA     24h   0mM       No-FA  12h   5mM         -0.02     0.9854 
       FA*time*butyrate  LA     24h   0mM       No-FA  24h   0mM         -0.25     0.7999 
       FA*time*butyrate  LA     24h   0mM       No-FA  24h   5mM          1.12     0.2664 
       FA*time*butyrate  LA     24h   0mM       No-FA  6h    0mM          1.68     0.0988 
       FA*time*butyrate  LA     24h   0mM       No-FA  6h    5mM          2.41     0.0193 
       FA*time*butyrate  LA     24h   5mM       LA     6h    0mM          2.35     0.0227 
       FA*time*butyrate  LA     24h   5mM       LA     6h    5mM          2.96     0.0045 * 
       FA*time*butyrate  LA     24h   5mM       No-FA  12h   0mM         -1.98     0.0533 
       FA*time*butyrate  LA     24h   5mM       No-FA  12h   5mM         -0.81     0.4197 
       FA*time*butyrate  LA     24h   5mM       No-FA  24h   0mM         -1.05     0.2990 
       FA*time*butyrate  LA     24h   5mM       No-FA  24h   5mM          0.33     0.7448 
       FA*time*butyrate  LA     24h   5mM       No-FA  6h    0mM          0.88     0.3823 
       FA*time*butyrate  LA     24h   5mM       No-FA  6h    5mM          1.61     0.1128 
       FA*time*butyrate  LA     6h    0mM       LA     6h    5mM          0.62     0.5365 
       FA*time*butyrate  LA     6h    0mM       No-FA  12h   0mM         -4.34     <.0001 
       FA*time*butyrate  LA     6h    0mM       No-FA  12h   5mM         -3.17     0.0025 
       FA*time*butyrate  LA     6h    0mM       No-FA  24h   0mM         -3.41     0.0013 
       FA*time*butyrate  LA     6h    0mM       No-FA  24h   5mM         -2.02     0.0485 
       FA*time*butyrate  LA     6h    0mM       No-FA  6h    0mM         -1.47     0.1482 
       FA*time*butyrate  LA     6h    0mM       No-FA  6h    5mM         -0.73     0.4666 
       FA*time*butyrate  LA     6h    5mM       No-FA  12h   0mM         -4.95     <.0001 
       FA*time*butyrate  LA     6h    5mM       No-FA  12h   5mM         -3.79     0.0004 
       FA*time*butyrate  LA     6h    5mM       No-FA  24h   0mM         -4.02     0.0002 
       FA*time*butyrate  LA     6h    5mM       No-FA  24h   5mM         -2.64     0.0109 
       FA*time*butyrate  LA     6h    5mM       No-FA  6h    0mM         -2.09     0.0418 
       FA*time*butyrate  LA     6h    5mM       No-FA  6h    5mM         -1.35     0.1816 
       FA*time*butyrate  No-FA  12h   0mM       No-FA  12h   5mM          1.17     0.2487 
       FA*time*butyrate  No-FA  12h   0mM       No-FA  24h   0mM          0.93     0.3568 
       FA*time*butyrate  No-FA  12h   0mM       No-FA  24h   5mM          2.31     0.0250 
       FA*time*butyrate  No-FA  12h   0mM       No-FA  6h    0mM          2.86     0.0060 * 
       FA*time*butyrate  No-FA  12h   0mM       No-FA  6h    5mM          3.60     0.0007 
       FA*time*butyrate  No-FA  12h   5mM       No-FA  24h   0mM         -0.24     0.8140 
       FA*time*butyrate  No-FA  12h   5mM       No-FA  24h   5mM          1.14     0.2585 
       FA*time*butyrate  No-FA  12h   5mM       No-FA  6h    0mM          1.70     0.0951 
       FA*time*butyrate  No-FA  12h   5mM       No-FA  6h    5mM          2.43     0.0184 * 
       FA*time*butyrate  No-FA  24h   0mM       No-FA  24h   5mM          1.38     0.1740 
       FA*time*butyrate  No-FA  24h   0mM       No-FA  6h    0mM          1.93     0.0583 * 
       FA*time*butyrate  No-FA  24h   0mM       No-FA  6h    5mM          2.67     0.0101 
       FA*time*butyrate  No-FA  24h   5mM       No-FA  6h    0mM          0.55     0.5823 
       FA*time*butyrate  No-FA  24h   5mM       No-FA  6h    5mM          1.28     0.2043 
       FA*time*butyrate  No-FA  6h    0mM       No-FA  6h    5mM          0.73     0.4669 
 
 
Analysis of Controls for Both Days 
 
For 8/11/03, the procedure was run in proc mixed using a subsampling term for well.  Some problems with the data – 
groups are very variable. 
 
 
  Type 3 Tests of Fixed Effects 
 
                                       Num     Den 
                         Effect         DF      DF    F Value    Pr > F 
 
                         cont_2          2     443     657.44    <.0001 
 
 
                                      Least Squares Means 
 
                                            Standard 
            Effect    cont_2    Estimate       Error      DF    t Value    Pr > |t| 
 
            cont_2    H2O250      667.96     28.0391     443      23.82      <.0001 
            cont_2    cum100     1677.22     30.0775     443      55.76      <.0001 
            cont_2    cum25       130.97     31.6323     443       4.14      <.0001 
 
 
                              Differences of Least Squares Means 
 
                                                 Standard 
       Effect    cont_2    cont_2    Estimate       Error      DF    t Value    Pr > |t| 
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       cont_2    H2O250    cum100    -1009.26     41.1199     443     -24.54      <.0001 
       cont_2    H2O250    cum25       536.99     42.2705     443      12.70      <.0001 
       cont_2    cum100    cum25      1546.25     43.6493     443      35.42      <.0001 
 
All significantly different. 
 
9/1/03, since only one well, anova was run.  Data set very variable – not confident about the results. 
 
Type 3 Tests of Fixed Effects 
 
                                       Num     Den 
                         Effect         DF      DF    F Value    Pr > F 
 
                         control         2     712     257.48    <.0001 
 
 
                                      Least Squares Means 
 
                                             Standard 
           Effect     control    Estimate       Error      DF    t Value    Pr > |t| 
 
           control    DH2O2        459.35     18.3452     712      25.04      <.0001 
           control    H2O2        1123.52     23.7868     712      47.23      <.0001 
           control    cum          509.58     35.8173     712      14.23      <.0001 
 
 
                               Differences of Least Squares Means 
 
                                                   Standard 
      Effect     control    control    Estimate       Error      DF    t Value    Pr > |t| 
 
      control    DH2O2-50uM H2O2-5uM    -664.18     30.0393     712     -22.11      <.0001 
      control    DH2O2-50uM cum25       -50.239     40.2421     712      -1.25      0.2123 
      control    H2O2-5uM   cum25        613.94     42.9964     712      14.28      <.0001 
 
Dh202 and cum not significantly different from each other. 
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Table B-7.  Summary of Fatty Acid and Butyrate Treatment Effects  
 
Treatments Results 
DHA incubation 
(72 h) 
DHA and butyrate 
co-incubation 
(Compared to LA treatment) 
• Did not induce lipid oxidation 
• Greater effect: ↑ basal MP (50 µM) 
• ↑ basal MP (dose dependent) 
 (Compared to LA and butyrate co- treatment) 
•
 
↑
 mitochondrial lipid oxidation (dose dependent)  
•
 Greater effect: ↑ lipid oxidation (5 mM Butyrate) 
•↓ MP (time dependent) 
• Greater effect: ↓ MP (24 h) 
Butyrate 
incubation 
(In the absence of fatty acid) 
•
 
↑
 lipid oxidation (no dose effect) 
Mitochondrion 
Apoptosis (?) 
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APPENDIX C 
 
RESULTS FROM PRELIMINARY EXPERIMENTS 
Result C-1: Mitochondrial Membrane Potential Dissipation in Viable Cells 
 
Purpose: To determine the utility of 2 fluorescence probes, TMRM and calcein AM, to measure 
mitochondrial membrane potential (MP) in viable YAMC cells. 
 
Rationale:  
The tetramethylrhodamine methyl ester perchlorate (TMRM) (Molecular Probes, #T668) is 
a lipophilic cationic fluorescent probe, which accumulates in the mitochondria in proportion to MP 
(77).  In comparison, calcein AM (Molecular probes, #C3100) is a cell-permeant dye that can be 
used to determine cell viability in most eukaryotic cells. In viable cells, the nonfluorescent calcein 
AM is converted to a green-fluorescent calcein after acetoxymethyl ester hydrolysis by intracellular 
esterases (Molecular probe). 
 
To determine the validity of TMRM and calcein AM to measure the change in MP in viable 
YAMC cells, following butyrate incubation with or without 50 µM DHA or LA pretreatment, cells 
were loaded with TMRM and calcein AM as indicated in the protocol.   
  
TMRM and Calcein dye loading protocol: 
1. Add 1 ml RPMI complete media with γ-IFN into each well of YAMC cells   
2. Add 1.0 µl TMRM (150 nM final conc.) 
3. Incubate at 33°C, at least 10 min  
4. Add 1.0 µl calcein-AM (1 µM final conc.) 
5. Incubate at 33°C, for another 10 min 
6. Aspirate off media with dyes 
7. Add 1 ml fresh Leibovitz media (without phenol red) 
8. Image for 0, 5, 10 and 15 min. 
 
Butyrate, isobutyrate (negative control), DHA and LA were added to the media as described in 
protocol # A-5.   Each experiment was designed to optimize the protocol, hence the order and 
duration of butyrate incubations varied.  Magnification power was set at 200 or 400, images of 
cells (about 30 cells per field) were captured by a phase-contrast, fluorescent, widefield inverted 
Nikon microscope.  The fluorescence excitation/emission wavelengths were 562/624 nm for 
TMRM, and 477/536 nm for calcein AM. Ten representative cells from each captured image were 
randomly selected for fluorescence intensity quantification. Data were plotted using mean (+/- 
SEM) average pixel intensity of all cells.   
  93  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Fig. C-1. Representative photomicrographs of YAMC cells illuminated following loading with TMRM at 
150 nM for 10 min and subsequent incubation with calcein AM at 1 µM for 10 min. Two images of each 
same field were captured using different excitation and emission filters. 
 
 
Results:  
1) A kinetic study (2002.02.15) was also performed to look at the effect of short duration butyrate 
treatment at 5 mM for up to 45 min, post DHA or LA treatments, on MP and cell viability. 
Butyrate incubation for up to 45 min did not induce MP dissipation, using TMRM and calcein AM 
as two fluorescence probes.  
 
2) A representative set of data (2002.03.07) is presented to show that DHA- and LA-BSA 
pretreatment, at 50 µM, did not alter MP, using TMRM as a fluorescent probe.  In this specific set 
of experiments, 5 mM butyrate treatment was incubated for 2, 6, 12 or 24 h, with or without 50 µM 
DHA or LA pre-treatment in YAMC cells for 72 h. See table Appendix C-1 for results.  
 
3) To optimize imaging outcome, YAMC cells treated with PUFA and butyrate were analyzed 
using confocal microscopy and TMRM (2002.05.10).  The results from 2003.03.07 (butyrate 
treatment dissipate MP) were not reproducible.  
 
Conclusion:  
We have previously demonstrated that MP was dissipated by butyrate incubation (5 mM) for 24 h 
(47).  This experiment using TMRM could not consistently reproduce the effect.  We conclude that 
TMRM might not be a suitable probe to measure MP dissipation in YAMC cells.   
 
References:   
Molecular probes 
http://www.probes.com (last accessed: May 20, 2004) 
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